SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934
Filed by the Registrant {X}
Filed by a Party other than the Registrant {_}
Check the appropriate box:
{ } Preliminary Proxy Statement {_} Confidential, for Use of the Commission
only (as permitted by Rule 14a-6(e)(2))
{X } Definitive Proxy Statement
{_} Definitive Additional Materials
{_} Soliciting Material Pursuant to Rule 14a-12
Bioenvision, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
{X} No fee required.
{_} Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
{_} Fee paid previously with preliminary materials.
{_} Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the form or schedule and the date of its filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing Party: (4) Date Filed:
--------------------------------------------------------------------------------
BIOENVISION, INC.
509 Madison Avenue, Suite 404
New York, NY 10022
(212)750-6700
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
Date: January 14, 2004
Time: 12:00 p.m., local Eastern time
Place: American Stock Exchange
86 Trinity Place
New York, NY 10006
Purposes of the Meeting:
. To amend our certificate of incorporation to (i)increase the authorized
number of shares of our common stock from 50,000,000 to 70,000,000 and
(ii)increase the authorized number of shares of our preferred stock from
10,000,000 to 20,000,000.
. To approve the adoption of our 2003 Stock Incentive Plan.
. To elect five directors to our Board of Directors.
. To transact any other business that may properly come before the meeting.
Record Date:
December 12, 2003 is the record date for the meeting. This means that holders
of our voting stock at the close of business on that date are entitled to:
. receive notice of the meeting; and
. vote at the meeting and any adjournment or postponement of the meeting.
Proxy Solicitation:
The enclosed proxy is solicited by the Board of Directors.
Annual Report:
We have enclosed a copy of our annual report for the fiscal year ended June
30, 2003 which is not a part of the proxy soliciting materials.
Voting:
Your vote is important. Please sign, date and return your proxy card promptly
so your shares can be represented, even if you plan to attend the meeting.
Please see the proxy card for instructions on how to vote. You can revoke a
proxy at any time prior to its exercise at the meeting by following the
instructions in the proxy statement or by attending the meeting and voting in
person.
Christopher B. Wood, M.D.
December 16, 2003 Chairman and Chief Executive Office
--------------------------------------------------------------------------------
BIOENVISION, INC.
509 Madison Avenue, Suite 404
New York, NY 10022
(212)750-6700
-----------------
PROXY STATEMENT
for
Annual Meeting of Stockholders
January 14, 2004
-----------------
This proxy statement is being mailed to you in connection with the
solicitation of proxies by the Board of Directors of Bioenvision, Inc. for use
at its annual meeting of stockholders and any adjournment of such meeting. The
meeting will be held on the date, at the time and place and for the purposes
indicated in the foregoing notice. This proxy statement, the foregoing notice
and the enclosed proxy card are first being sent to stockholders on or about
December 16, 2003.
ABOUT THE MEETING
Who can vote?
You can vote if, as of the close of business on December 12, 2003 you were a
stockholder of record of our common stock or our Series A Convertible
Participating Preferred Stock ("Series A Preferred Stock"). On that date,
18,607,985 shares of our common stock were outstanding and entitled to vote and
5,440,000 shares of our Series A Preferred Stock were outstanding and entitled
to vote. Our common stock and Series A Preferred Stock are the only classes of
voting stock outstanding. On each matter to be voted upon at the meeting, other
than the amendment of our certificate of incorporation and adoption of our stock
option plan, holders of our common stock and Series A Preferred Stock will vote
together as a single class. With respect to the amendment of our certificate of
incorporation, the holders of our common stock and Series A Preferred Stock will
each vote as a separate class as well as together as a single class and with
respect to the adoption of the 2003 Stock Incentive Plan the Series A Preferred
Stock will vote as a single class as well as together with the common stock as a
single class. Each share of common stock is entitled to one vote. Each share of
Series A Preferred Stock is convertible into 2 shares of common stock. When the
Series A Preferred Stock votes as a separate class, each share of Series A
Preferred Stock will be entitled to one vote. However, when the Series A
Preferred Stock votes together with the common stock as a single class, each
share of common stock will have one vote and each share of Series A Preferred
Stock, based on the conversion ratio, will have 2 votes.
What constitutes a quorum?
The presence at the meeting, in person or by proxy, of 14,743,993 shares
representing a majority of the votes that may be cast by all outstanding shares
of common stock and Series A Preferred Stock as of the record date, voting
together as a single class, must be present to hold the meeting. However, in the
event that a quorum is not present, the holders of our common stock and Series A
Preferred Stock present in person or by proxy entitled to cast a majority of the
votes that all such shares which are present in person or by proxy may cast,
when the common stock and Series A Preferred Stock vote together as a single
class, shall have the power to adjourn the meeting from time to time until a
quorum is present. Abstentions from voting and broker "non-votes" will be
counted towards a quorum. A broker "non-vote" occurs when the nominee holding a
stockholder's shares does not vote on a particular proposal because the nominee
does not have
discretionary voting power on that item and has not received instructions from
the stockholder.
What vote is required and what is the method of calculation?
Approval of the amendment to our certificate of incorporation will require:
. the affirmative vote of 14,743,993, a majority of the votes that may be
cast by all outstanding shares of common stock and Series A Preferred
Stock voting together as a class;
. the affirmative vote of 9,303,992, a majority of the outstanding shares of
common stock voting as a separate class; and
. the affirmative vote of 2,720,000, a majority of the outstanding shares of
Series A Preferred Stock voting as a separate class.
Approval of the 2003 Stock Incentive Plan will require:
. the affirmative vote of 14,743,993, a majority of the votes that may be
cast by all outstanding shares of common stock and Series A Preferred
Stock voting together as a class; and
. the affirmative vote of 2,720,000, a majority of the outstanding shares of
Series A Preferred Stock voting as a separate class.
The nominees for director who receive the most votes for the number of
positions to be filled will be elected. Any other matter that may be voted on at
the meeting will generally require the affirmative vote of 14,743,993, a
majority of the votes that may be cast by the shares of common stock and Series
A Preferred Stock, voting together as a class, present in person or represented
by proxy at the meeting and entitled to vote thereon. Abstentions will have no
effect on the election of directors, and abstentions or broker "non-votes" will
not be counted for or against any other matters that may be acted on at the
meeting. With respect to the amendment of our certificate of incorporation and
adoption of our stock option plan, because approval requires the affirmative
vote of a majority of the votes that may be cast by all outstanding shares of
the relevant class, abstentions and broker non-votes will have the effect of a
no vote.
What matters will be voted on?
Our Board of Directors does not intend to bring any other matters before the
meeting except the approval of the amendment to our certificate of
incorporation, the approval of the adoption of our 2003 Stock Incentive Plan,
and the election of directors. The Board is not aware of anyone else who will
submit any other matters to be voted on. However, if any other matters properly
come before the meeting, the people named on the proxy card, or their
substitutes, will be authorized to vote on those matters in their own judgment.
How do I vote by proxy?
When you return your properly signed and dated proxy card prior to the
meeting, your shares will be voted in accordance with your instructions marked
on the proxy card. If you sign your proxy card but do not specify how you want
your shares to be voted, they will be voted as recommended by the Board of
Directors.
Can I change my vote after I return my proxy card?
Yes. You can change or revoke your proxy at any time before the meeting by
notifying us in writing, by sending another executed proxy dated later than the
first proxy card or by attending the meeting and voting in
-2-
person.
Can I vote in person at the meeting instead of voting by proxy?
Yes. However, we encourage you to complete and return the enclosed proxy card
to ensure that your shares are represented and voted. If you attend the meeting
in person, you may then vote in person even though you returned your proxy card.
Who pays for this proxy solicitation?
We do. We will pay all costs in connection with the meeting, including the
cost of preparing, assembling and mailing proxy materials, handling and
tabulating the proxies returned, and charges of brokerage houses, nominees and
fiduciaries in forwarding proxy materials to our beneficial owners.
-----------------------------------------------------------
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of the adequacy
or accuracy of the disclosure in this proxy statement. Any representation to
the contrary is a criminal offense.
-----------------------------------------------------------
This proxy statement provides you with detailed information about the
proposed amendment to our certificate of incorporation, the adoption of our
stock option plan and related matters. We encourage you to read this entire
document carefully.
We make forward-looking statements in this proxy statement that are
subject to risks and uncertainties. In some cases, you can identify these
statements by forward-looking words such as "may," "might," "will," "should,"
"expects," "plans," "anticipates," "believes," "estimates," "predicts,"
"potential" or "continue," the negative of these terms and other comparable
terminology. These forward-looking statements which are subject to risks,
uncertainties and assumptions about us, may include projections of our future
financial performance, or anticipated growth strategies and anticipated trends
in our business. These statements are only predictions based on our current
expectations and projections about future events. There are important factors
that could cause our actual results, level of activity, performance or
achievements to differ materially from the results, level of activity,
performance or achievements expressed or implied by the forward-looking
statements. Although we believe the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements. Moreover, neither we nor any
other person assumes responsibility for the accuracy and completeness or any of
these forward-looking statements.
PROPOSAL 1--AMENDMENT TO CERTIFICATE OF INCORPORATION
(Item 1 on Proxy Card)
The Company is proposing to amend its Articles of Incorporation to
(i)increase the number of shares of authorized common stock from 50,000,000
shares to 70,000,000 shares and (ii)increase the number of shares of preferred
stock from 10,000,000 shares to 20,000,000 shares. On the record date,
18,607,985 shares of common stock were outstanding, 5,440,000 shares of
preferred stock were outstanding and 3,000,000 shares of common stock are to be
reserved for issuance under the 2003 Stock Incentive Plan, if approved.
-3-
Purpose and Effect of the Amendment
The principal purpose of the proposed amendment to the Articles of
Incorporation, attached hereto as Annex A, is to authorize additional shares of
common stock and preferred stock which will be available in the event the Board
of Directors determines that it is necessary or appropriate to permit future
stock dividends, to raise additional capital through the sale of equity
securities, to acquire another company or its assets, to establish strategic
relationships with corporate partners and to provide equity incentives to
employees and officers or for other corporate purposes. The availability of
additional shares of stock is particularly important in the event that the Board
of Directors needs to undertake any of the foregoing actions on an expedited
basis and thus to avoid the time and expense of seeking stockholder approval in
connection with the contemplated issuance of stock. If the amendment is approved
by the stockholders, the Board does not intend to solicit further stockholder
approval prior to the issuance of any additional shares of common stock or
preferred stock, except as may be required by the Company's certificate of
incorporation, certificate of designations or applicable law.
The increase in authorized common stock and preferred stock will not have
any immediate effect on the rights of existing stockholders. However, the Board
will have the authority to issue authorized common stock or preferred stock
without requiring future stockholder approval of such issuances, except as may
be required by the Company's certificate of incorporation, certificate of
designations or applicable law. To the extent that additional authorized shares
are issued in the future, they may decrease the existing stockholders'
percentage equity ownership and, depending on the price at which they are
issued, could be dilutive to the existing stockholders.
The increase in the authorized number of shares of common stock or
preferred stock and the subsequent issuance of such shares could have the effect
of delaying or preventing a change in control of the Company without further
action by the stockholders. Shares of authorized and unissued common stock and
preferred stock could, within the limits imposed by applicable law, be issued in
one or more transactions which would make a change in control of the Company
more difficult, and therefore less likely. Any such issuance of additional stock
could have the effect of diluting the earnings per share and book value per
share of outstanding shares of common stock or preferred stock and such
additional shares could be used to dilute the stock ownership or voting rights
of a person seeking to obtain control of the Company.
The Board of Directors is not currently aware of any attempt to take over
or acquire the Company. While it may be deemed to have potential anti-takeover
effects, the proposed amendment to increase the authorized common stock and
preferred stock is not prompted by any specific effort or takeover threat
currently perceived by management.
We do not have any current intentions, plans, arrangements, commitments or
understandings to issue any shares of its capital stock except in connection
with the 2003 Stock Incentive Plan.
Vote Required and Board of Director's Recommendation
Approval of this amendment to our certificate of incorporation will
require (i)the affirmative vote of a majority of the votes that may be cast by
all outstanding shares of common stock and Series A Preferred Stock voting
together as a class, (ii)the affirmative vote of a majority of the outstanding
shares of common stock voting as a separate class, and (iii)the affirmative vote
of a majority of the outstanding shares of Series A Preferred Stock voting as a
separate class. The Board of Directors recommends voting "FOR" approval of the
amendment to our certificate of incorporation.
-4-
PROPOSAL 2--APPROVAL OF ADOPTION OF THE 2003 STOCK INCENTIVE PLAN
(Item 2 on Proxy Card)
Our Board of Directors has adopted, subject to the approval of our
stockholders, the 2003 Stock Incentive Plan, attached hereto as Annex B. The
plan was adopted to recognize the contributions made by our employees, officers,
consultants, and directors, to provide those individuals with additional
incentive to devote themselves to our future success and to improve our ability
to attract, retain and motivate individuals upon whom our growth and financial
success depends.
The key provisions of the plan are as follows:
Eligibility and Administration.
The plan authorizes the Board of Directors or the compensation committee
(the "Administrator"), to (i)select the participants who are to be granted
options, restricted shares or performance units, (ii)determine the number of
shares of Common Stock to be granted to each participant, (iii)designate
options, to the extent the award consists of options, as incentive stock options
or nonstatutory stock options, (iv)determine the vesting schedule and
performance criteria, if any, for restricted shares and performance units and
(v)determine to what extent the awards may be transferable. As of the date
hereof, there are approximately 7 employees who are currently eligible to
participate in the plan under the Company's policies. All directors and
consultants are currently eligible to participate in the plan. The
Administrator's interpretations and construction of the plan are final and
binding on the Company.
Shares Available for Issuance Under the Plan
The stock subject to options granted under the plan are shares of the
Company's authorized but unissued or reacquired shares of Common Stock. On
December 12, 2003, the closing price of the common stock on the American Stock
Exchange of the Common Stock was $4.75 per share. As of December 12, 2003,
3,000,000 shares were available for future grants of options and, assuming this
Proposal 2 is approved by the stockholders. On the same date, there were
18,607,985 shares of Common Stock outstanding.
Grant, Exercise and other Terms of Awards.
Options issued under the plan are designated as either incentive stock
options or nonstatutory stock options. Incentive stock options are options
meeting the requirements of Section 422 of the Code, and nonstatutory options
are options not intended to so qualify.
The exercise price of options granted under the plan may not be less
than 100% of the fair market value of the Common Stock of the Company (as
defined by the plan) on the date of the grant. With respect to any participant
who owns stock representing more than 10% of the voting rights of the
outstanding Common Stock of the Company, the exercise price of any incentive
stock option granted must equal at least 110% of the fair market value of the
Common Stock on the grant date, and the maximum term of any such incentive stock
option must not exceed five years.
Options, restricted shares and performance units are evidenced by
written award agreements in a form approved by the Administrator from time to
time and no award is effective until the applicable award agreement has been
executed by both parties thereto. Options granted under the plan may become
exercisable in cumulative increments over a period of months or years, or
otherwise, as determined by the Administrator. The purchase price of options
shall be paid in cash; provided, however, that if the applicable award agreement
so provides, or the Administrator, in its sole discretion otherwise approves
thereof, the purchase price may be paid in shares of Common Stock having a fair
market value on the exercise date equal to the exercise price or in any
combination of cash and shares of Common Stock, as long as the sum of the cash
so paid
-5-
and the fair market value of the shares so surrendered equals the aggregate
purchase price. In addition, the Administrator may permit deferred compensation
elections by certain directors and executive officers. The award agreement
evidencing the restricted shares and/or performance units shall set forth the
terms upon which the Common Stock subject to any awards or the achievement of
any cash bonus may be earned.
No options granted under the plan are exercisable after the expiration
of ten years (or less in the discretion of the Administrator) from the date of
the grant, and no incentive stock options granted under the Amended Award Plan
to a participant who owns more than ten percent of the total combined voting
power of all classes of outstanding stock of the Company shall be exercisable
after the expiration of five years (or less, in the discretion of the
Administrator) from the date of the grant. The aggregate fair market value (as
of the respective date or dates of grant) of the shares of Common Stock
underlying the incentive stock options that are exercisable for the first time
by a participant during any calendar year under the plan and all other similar
plans maintained by the Company may not exceed $100,000. If a participant ceases
to be an employee of the Company for any reason other than his or her death,
Disability or Retirement (as such terms are defined in the plan), such
participant shall have the right, subject to certain restrictions, to exercise
that option at any time within ninety days (or less, in the discretion of the
Administrator) after cessation of employment, but, except as otherwise provided
in the applicable award agreement, only to the extent that, at the date of
cessation of employee, the participant's right to exercise such option had
vested and had not been previously exercised. The Administrator, in its sole
discretion, may provide that the option shall cease to be exercisable on the
date of such cessation if such cessation arises by reason of termination for
Cause (as such term is defined in the Amended Award Plan) or if the participant
becomes an employee, director or consultant of an entity that the Administrator
determines is in direct competition with the Company.
In the event a participant dies before such participant has fully
exercised his or her option, then the option may be exercised at any time within
twelve months after the participant's death by the executor or administrator of
his or her estate or by any person who has acquired the option directly from the
participant by bequest or inheritance, but except as otherwise provided on the
applicable award agreement, only to the extent that, at the date of death, the
participant's right to exercise such option had vested pursuant to the terms of
the applicable award agreement and had not been forfeited or previously
exercised.
In the event a participant ceases to be an employee of the Company by
reason of Disability, such participant shall have the right, subject to certain
restrictions, to exercise the option at any time within twelve months (or such
shorter period as the Administrator may determine) after such cessation of
employment, but only to the extent that, at the date of cessation of employment,
the participant's right to exercise such option had previously vested pursuant
to the terms of the applicable award agreement and had not previously been
exercised.
In the event a participant ceases to be an employee of the Company by
reason of Retirement, such participant shall have the right, subject to certain
restrictions, to exercise the option at any time within ninety days (or such
longer or shorter period as the Administrator may determine) after cessation of
employment, but only to the extent that, at the date of cessation of employment,
the participant's right to exercise such option had vested pursuant to the terms
of the applicable award agreement and had not previously been exercised.
Adjustment of Awards Upon Certain Events.
If the Company merges with another corporation and the Company is the
surviving corporation in such merger and under the terms of such merger the
shares of Common Stock outstanding immediately prior to the merger remain
outstanding and unchanged, each outstanding award shall continue to apply to the
shares subject thereto and will also pertain and apply to any additional
securities and other property, if any, to which a holder of the number of shares
subject to the option would have been entitled as a
-6-
result of the merger.
In the event all or substantially all of the assets of the Company are
sold, the Company engages in a merger where the Company does not survive or the
Company is consolidated with another corporation, each participant shall receive
immediately before the effective date of such sale, merger or consolidation
restricted shares and the value of any performance units to which the
participant is then entitled (regardless of any vesting condition) and each
outstanding option will become exercisable (without regard to the vesting
provisions thereof) for a period of at least 30 days ending five days prior to
the effective date of the transaction. Notwithstanding the foregoing, the
surviving corporation may, in its sole discretion, (i) (a) grant to participants
with options, options to purchase shares of the surviving corporation upon
substantially the same terms as the options granted under the plan, (b) tender
to all participants with restricted shares, an award of restricted shares of the
surviving or acquiring corporation, and (c) tender to all participants with
performance units, an award of performance units of the surviving or acquiring
corporation, or (ii) (a) permit participants with restricted shares to receive
unrestricted shares immediately prior to the effective date of any transaction,
(b) permit participants with performance units to receive cash with respect to
the value of any performance units immediately before the effective date of the
transaction and (c) provide participants with options the choice of exercising
the option prior to the consummation of the transaction or receiving a
replacement option.
Notwithstanding anything to the contrary and except as otherwise
expressly provided in the applicable award agreement, the vesting or similar
installment provisions relating to the exercisability of any award, option or
replacement option tendered as described in the previous sentence shall be
accelerated, and the participant with restricted shares or performance units
shall become fully vested, and the participant with options shall have the
right, for a period of at least 30 days, to exercise such options; provided that
such accelerations of vesting and exercisability shall occur only in the event
that the participant's employment with or services for the Company should
terminate within two years following a Change of Control (as defined in the
plan), unless such employment or services are terminated by the Company for
Cause (as defined in the plan) or by the participant voluntarily without Good
Reason (as defined in the plan), or such employment or services are terminated
due to the death or Disability of the participant. Notwithstanding the
foregoing, no incentive stock option shall become exercisable pursuant to the
foregoing without the participant's consent, if the result would be to cause
such option not to be treated as an incentive stock option.
The number of shares of Common Stock covered by the plan, the number of
shares of Common Stock covered by each outstanding option, restricted share and
performance unit and the exercise price of any options shall be proportionately
adjusted for any increase or decrease in the number of issued shares of Common
Stock resulting from a subdivision or consolidation of such shares or a stock
split or the payment of a stock dividend (but only of Common Stock) or any other
increase or decrease in the number of issued shares effected without receipt of
consideration by the Company.
Transfer of Awards.
Unless an award is designated transferable by the Administrator upon
grant, during the lifetime of the participant who has been granted an award, the
award shall be shall not be assignable or transferable. No incentive stock
option may be designated as transferable. In the event of the participant's
death, any nontransferable award shall be transferable by the participant's will
or the laws of descent and distribution.
Amendment and Termination.
The plan will continue in effect until terminated by the Board of
Directors or until expiration of the plan on November 17, 2013. The Board may
suspend or discontinue the plan or revise or amend it.
-7-
Federal Income Tax Consequences.
The following discussion is intended only as a general summary of the
federal income tax consequences to participants and the Company with respect to
the plan. The discussion is based on current laws which are subject to change at
any time or which may be interpreted differently. The discussion does not
address tax consequences under the laws of any state, local or foreign
jurisdiction, nor does it address federal and state estate, inheritance and gift
taxes. Further, the tax treatment of each Participant will depend in part upon
such Participant's particular tax situation.
The Code provides favorable tax treatment for incentive stock options.
Incentive stock options are subject to certain requirements which are set forth
in the plan. Generally, upon the grant of an incentive stock option, and upon
the exercise of the incentive stock option during employment or within three
months after termination of employment, the optionee will not recognize any
income. However, any appreciation in the value of the shares from the date of
grant through the date of exercise will generally be an item of adjustment in
determining the optionee's potential liability for alternative minimum tax for
the taxable year of exercise. The alternative minimum tax may produce a higher
tax liability than the regular income tax applicable to the optionee.
The sale or disposition of Common Stock purchased upon exercise of an
incentive stock option is generally a taxable event. The optionee will recognize
a gain or loss in an amount equal to the difference between his or her basis in
the Common Stock (normally the exercise price) and the proceeds from the sale or
disposition. If the Common Stock acquired pursuant to an incentive stock option
is not sold or otherwise disposed of within two years from the date of grant of
the incentive stock option and is held for at least one year after exercise of
the incentive stock option (the "Holding Period"), any gain or loss resulting
from the sale or disposition of the Common Stock will be treated as long-term
capital gain or loss. If Common Stock acquired upon exercise of an incentive
stock option is disposed of prior to the expiration of the Holding Period (a
"Disqualifying Disposition"), the excess of the fair market value of the Common
Stock on the date of exercise over the exercise price, before or the excess of
the sale price over the exercise price, whichever is less, will be treated as
ordinary income in the year of disposition. However, any additional gain will be
taxed as capital gain (i.e., the excess, if any, of the sales price over the
fair market value on the date of exercise). If an optionee disposes of the
Common Stock more than one year after the date of exercise, such capital gain or
loss will be treated as long-term capital gain or loss.
The Company normally is not entitled to a deduction with respect to
incentive stock options. However, in the event of a Disqualifying Disposition,
the Company is entitled to deduct the ordinary income realized by the optionee.
Optionees are required to notify the Company of any Disqualifying Dispositions.
No taxable income will be realized by an optionee upon the grant of a
nonstatutory stock option. Upon exercise of a nonstatutory stock option, the
optionee must recognize as ordinary income the excess of the fair market value
of the Common Stock on the date of exercise over the exercise price. The Company
may deduct the amount includible in the employee's income. An optionee's new
basis in the Common Stock acquired upon exercise of a nonstatutory stock option
will generally be the fair market value of the shares on the date of exercise.
Upon a subsequent disposition of such Common Stock, the optionee generally will
realize a capital gain or loss to the extent of any intervening appreciation or
depreciation. If an optionee disposes of the Common Stock more than one year
after the date of exercise, such capital gain or loss will be treated as
long-term capital gain or loss. If the optionee makes a deferred compensation
for stock option gains, the optionee will generally recognize ordinary income
upon later collecting benefits. In these cases. the Company's tax deductions
would coincide in timing and amount with the optionee's income recognition.
The receipt of restricted shares of stock of the Company or performance
based units in exchange for services provided to the Company may be a taxable
event to the
-8-
employee. The restricted shares generally are subject to vesting requirements;
however during the taxable year in which such shares are first either vested
(i.e. not subject to a substantial risk of being forfeited by the employee) or
transferable, the employee will have to report as ordinary income from
compensation an amount of income equal to the difference between the fair market
value of such shares at the time of vesting or removal of transfer restrictions
over the amount paid for such shares, which amount paid generally will be zero.
So long as liability under section 16(b) of the 1934 Act applies to the employee
with respect to restricted shares, he or she will be deemed not to have yet
incurred a taxable event. If performance based units are received subject to
either vesting requirements or restrictions on transferability, the same rules
apply as with restricted shares. If performance based units are not so
restricted, the employee generally will incur taxable ordinary compensation
income in an amount equal to the fair market value of such units in the year
received, less the amount, if any, paid for such units.
New Plan Benefits
The Administrator has made the determinations with respect to Awards
that will occur if the plan receives approval.
2003 Stock Incentive Plan
-------------------------
Name and Position # of securities Grant Date
----------------- underlying options ----------
------------------
Christopher B. Wood, M.D., 500,000 12/31/02
Chairman of the Board and Chief
Executive Officer
David P.Luci, Director of Finance, 500,000 3/31/03
General Counsel and Corporate
Secretary
Hugh Griffith, Commercial Director 300,000 10/23/02
Ian Abercrombie, Sales Manager 50,000 10/23/02
Vikki Charlton, Operations 20,000 1/9/03
Administrator
Executive Group 1,300,000
Non-Executive Director Group N/A
Non-Executive Officer Employee Group 70,000
Vote Required and Board of Director's Recommendation
Approval of the plan will require the affirmative vote of a majority
of the votes that may be cast by all outstanding shares of common stock and
Series A Preferred Stock voting together as a class, and the affirmative vote of
a majority of the outstanding shares of Series A Preferred Stock voting as a
separate class. The Board of Directors recommends voting "FOR" approval of the
plan.
PROPOSAL 3--ELECTION OF DIRECTORS
(Item 3 on Proxy Card)
At the meeting, the stockholders will elect five directors to hold office
until the annual meeting of stockholders in 2004 and until their respective
successors have been duly elected and qualified. The Board has nominated the
individuals listed below to serve as directors. All nominees are currently
members of the Board of Directors. Unless contrary instructions are given, the
shares represented by a properly executed proxy will be voted "FOR" the election
of each of the individuals listed below. The five nominees receiving a plurality
of the votes cast for director
-9-
will be elected. Should any nominee become unavailable to accept election as a
director, the persons named in the enclosed proxy will vote the shares which
they represent for the election of such other person as the Board of Directors
may recommend. The Board of Directors does not have a nominating or similar
committee. The Board of Directors recommends voting "FOR" the nominees for
director.
Nominees for Election of Directors
The names, ages as of November 12, 2003 and existing positions with the
Company, if any, are as follows:
Name of Individual Age Position with Bioenvision
------------------ --- -------------------------
Christopher B. Wood, M.D. 57 Chairman of the Board and Chief
Executive Officer
Jeffrey B. Davis 40 Director
Thomas Scott Nelson, C.A. 64 Director
Steven A. Elms 39 Director
Andrew Schiff, M.D. 38 Director
The name, principal occupation for the last five years, selected
biographical information and the period of service as a director of the Company
of each of the nominees is set forth below.
Christopher B. Wood, M.D. has served as our Chairman of the Board and Chief
Executive Officer since January 1999. From January 1997 to December 1998, Dr.
Wood was Chairman of Eurobiotech, Inc., a Delaware company. From March 1994 to
January 1997, Dr. Wood was a specialist surgeon in the National Health Service,
United Kingdom. From April 1979 to March 1991, Dr. Wood was a specialist surgeon
at The Royal Postgraduate Medical School, London, England. Dr. Wood holds an
M.D. from the University of Wales School of Medicine and the Fellowship of the
Royal College of Surgeons of Edinburgh.
Thomas Scott Nelson, C.A. was named a director in May 1998. Mr. Nelson served as
our Chief Financial Officer from May 1998 to September 2002. From 1996 to 1999,
Mr. Nelson served as the Director of Finance of the Management Board of the
Royal & Sun Alliance Insurance Group. From 1991 to 1996, Mr. Nelson served as
Group Finance Director of the Main Board of Sun Alliance Insurance Group. He has
served as Chairman of the United Kingdom insurance industry committee on
European regulatory, fiscal and accounting issues. He has also worked with
Deloitte in Paris and as a consultant with PA Consultants Management. Mr. Nelson
is a Member of Institute of Chartered Accountants of Scotland and a Fellow of
the Institute of Cost and Management Accountants. Mr. Nelson holds a B.A. degree
from Cambridge University.
Jeffrey B. Davis was named a director in February 2002. Mr. Davis has extensive
experience in investment banking, and corporate development and financing for
development stage companies. Mr. Davis serves as President of SCO Financial
Group LLC and SCO Securities LLC. He served as Senior Vice President and Chief
Financial Officer of HemaSure, Inc., a publicly traded development stage
healthcare technology company from November 1995 to April 1997. Prior to that,
from June 1990 to November 1995, Mr. Davis was Vice President, Corporate
Finance, at Deutsche Morgan Grenfell, both in the U.S. and Europe. Mr. Davis
also served in senior marketing and product management positions at AT&T Bell
Laboratories and Philips Medical Systems North America, where he was also a
member of the technical staff.
Steven A. Elms was named a director in May 2002. Mr. Elms serves as a Managing
Director of the Perseus-Soros BioPharmaceutical Fund. For five years prior to
joining Perseus-Soros, Mr. Elms was a Principal in the Life Science Investment
Banking group of Hambrecht & Quist (now J.P. Morgan H&Q). During his five years
at H&Q, Mr. Elms was involved in over 60 financing and M&A transactions, helping
clients raise in excess of $3.3 billion of capital. Mr. Elms' primary areas of
focus were the genomics and drug discovery technology sectors.
-10-
Andrew Schiff, M.D. was named a director in May 2002. Dr. Schiff currently
serves as a Managing Director of Perseus-Soros Biopharmaceutical Fund. Over the
last 10 years, Schiff has practiced internal medicine at The New York
Presbyterian Hospital where he maintains his position as a Clinical Assistant
Professor of Medicine. In addition, he has also been a partner of a small family
run investment fund, Kuhn, Loeb & Co since September 1993.
Vote Required and Board of Director's Recommendation
The election to the Board of Directors of each of the nominees will
require the affirmative vote of a majority of the votes that may be cast by all
outstanding shares of common stock and Series A Preferred Stock voting together
as a class. The Board of Directors recommends voting "FOR" the election to the
Board of Directors of each of the five nominees.
BOARD OF DIRECTORS; COMMITTEES
The Board of Directors currently has two standing committees; the Audit
Committee, and the Compensation Committee. The Board of Directors does not have
a standing Nominating Committee.
The Audit Committee is comprised of Messrs. Elms, Schiff and Nelson;
with Mr. Elms serving as Chairman of the Audit Committee. All current and
proposed Audit Committee members are independent, as independence is defined in
Section 121(A) of the AMEX's listing standards except for Mr. Nelson who was he
was an employee of the Company until September 2002. The Audit Committee
recommends the independent accountants appointed by the Board of Directors to
audit our the financial statements, which includes an inspection of our books
and accounts, and reviews with such accountants the scope of their audit and
their report thereon, including any questions and recommendations that may arise
relating to such audit and report or our internal accounting and auditing system
procedures.
The Compensation Committee is comprised of Messrs. Davis and Schiff;
with Mr. Davis serving as Chairman of the Compensation Committee. The function
of the Compensation Committee is to review and approve the compensation of
executive officers and establish targets and incentive awards under our
incentive compensation plans.
During the fiscal year ended June 30, 2003, (i) the Board of Directors
held 8 meetings; the Audit Committee held 4 meetings and (iii) the compensation
committee did not hold any meetings. During the fiscal years ended June 30,
2003, each director attended at least 75% of the meetings of the Board of
Directors and 100% of the total number of meetings of committees on which he
served.
Compensation of Directors
Our policy is that non-management directors are entitled to receive a
director's fee of $1,000 per meeting for attendance at meetings of the Board of
Directors, and are reimbursed for actual expenses incurred in respect of such
attendance. We do not separately compensate employees for serving as directors.
We do not provide additional compensation for committee participation or special
assignments of the board of directors.
EXECUTIVE AND SENIOR OFFICERS
The following sets forth the positions with the Company, ages as of
November 12, 2003 and selected biographical information for the executive and
senior officers of the Company who are not directors.
-11-
David P. Luci, C.P.A., Esq. has served as Director of Finance, General
Counsel and Corporate Secretary since July 2002. From September 1994 to July
2002, Mr. Luci served as a corporate associate at Paul, Hastings, Janofsky &
Walker LLP (New York office). Prior to that, Mr. Luci served as a senior auditor
at Ernst & Young LLP (New York office). Mr. Luci is a certified public
accountant. He holds a Bachelor of Science in Business Administration with a
concentration in accounting from Bucknell University and a J.D. from Albany Law
School of Union University.
Hugh S. Griffith has served as Commercial Director (Europe) of
Bioenvision, Ltd., a wholly-owned sales and marketing subsidiary of the Company
since October 2002. From January 2002 to October 2002, Mr. Griffith served as
Executive Commercial Director of QuantaNova Ltd. From January 2000 to December
2001, Mr. Griffith served as Senior Business Unit Manager at Abbott
Laboratories, Ltd. where he was responsible for strategic development,
implementation and commercialization of a new neonatology business unit. This
role encompassed the management of the sales force, marketing, PR, policy and
healthcare liaison teams whilst also directing the clinical development
programme for the neonatology portfolio. From April 1998 to January 2000, Mr.
Griffith was the HIV Business Unit Manager at Abbott Laboratories Ltd where he
was responsible for the profitability of the HIV franchise. Mr Griffith managed
the Norvir capsule crisis including the fully comprehensive named patient
programme. At Abbott Laboratories Ltd., Mr. Griffith also served as Business
Development Manager (July 1997 to April 1998) and as Area Sales Manager (October
1995 to July 1997). Mr. Griffith holds a Masters of Business Administration from
Cardiff Business School, a Diploma of Marketing and a Bachelor of Science in
Honours Biology from University of Stirling.
-12-
Report of the Audit Committee of the Board of Directors*
The board of directors' audit committee carries out oversight functions
with respect to the preparation, review and audit of the Company's financial
statements and operates under a written charter adopted by the board of
directors, which is attached to this proxy statement as Annex C. The audit
committee members are independent within the meaning of the applicable AMEX
listing standards except for Mr. Nelson who was an employee of the Company until
September, 2002. The development, maintenance and evaluation of internal
controls and procedures and the financial reporting system, the maintenance of
appropriate accounting and financial reporting principles or policies and the
preparation of financial statements in accordance with generally accepted
accounting principles are the responsibility of the Company's management. The
Company's independent auditors perform an independent audit of the Company's
consolidated financial statements in accordance with generally accepted auditing
standards and issue a report thereon. The audit committee's responsibility is to
monitor and oversee the foregoing functions. A brief description of the audit
committee's responsibilities is set forth under the caption "-- Board of
Directors; Committees."
The audit committee has met and held discussions with management and the
independent auditors with respect to the Company's consolidated financial
statements for fiscal year ending June 30, 2003 and related matters. Management
advised the committee that the Company's consolidated financial statements were
prepared in accordance with generally accepted accounting principles and the
committee has reviewed and discussed the consolidated financial statements with
management and the Company's independent auditors. The independent auditors
presented to and reviewed with the audit committee the matters required to be
discussed by Statement on Auditing Standards No. 61 (Communication with Audit
Committees). The Company's independent auditors also provided to the committee
the written disclosures required by Independence Standards Board Standard No. 1
(Independence Discussions with Audit Committees) and in connection therewith the
committee discussed with the independent auditors their views as to their
independence. In undertaking its oversight function, the audit committee relied,
without independent verification, on management's representation that the
financial statements have been prepared with integrity and objectivity and in
conformity with accounting principles generally accepted in the United States of
America and on the representations of the independent auditors included in their
report on the Company's financial statements.
Based on the audit committee's considerations, discussions with
management and the independent auditors as described above, the audit committee
recommended to the board of directors that the audited consolidated financial
statements be included in the Company's Annual Report on the Form 10-K for the
fiscal year ended June 30, 2003 to be filed with the Securities and Exchange
Commission (the "Commission").
Audit Committee
Steven A. Elms
Andrew Schiff, M.D.
Thomas Scott Nelson, C.A.
--------
* The material in this report is not "solicitation material," is not deemed
filed with the Commission, and is not incorporated by reference in any filing of
the Company under the Securities Act of 1933 (the "Securities Act") or the
Securities Exchange Act of 1934 ("Exchange Act"), whether made before or after
the date hereof and irrespective of any general incorporation language in any
filing.
-13-
INDEPENDENT AUDITOR
Fees billed to Company by Grant Thorton LLP for Fiscal 2002
Audit Fees:
Audit fees billed to the Company by Grant Throrton LLP for the audit of
the Company's annual financial statements for the fiscal year ended June 30,
2003 included in the Company's annual report on Form 10-K and the review of
interim financial statements included in the Company's quarterly reports on Form
10-Q totaled $160,000.
Financial Information Systems Design and Implementation Fees:
The Company did not engage Grant Thorton LLP to provide advice to the
Company regarding financial information systems design and implementation during
the fiscal year ended June 30, 2003.
All Other Fees:
Fees billed to the Company by Grant Thorton LLP for all other non-audit
services rendered to the Company for the fiscal year ended June 30, 2003,
including tax related services, totaled $46,900.
The audit committee of the Board of Directors was advised of the
services provided by Grant Thorton LLP that are unrelated to the audit of the
annual fiscal year end financial statements and the review of interim financial
statements and has considered whether the provision of such services is
compatible with maintaining Grant Thorton LLP's independence as the Company's
independent auditor.
-14-
EXECUTIVE COMPENSATION
The following table sets forth information for each of the fiscal years
ended June 30, 2003, 2002 and 2001 concerning the compensation paid and awarded
to all individuals serving as (a) our chief executive officer, (b) each of our
four other most highly compensated executive officers (other than our chief
executive officer) at the end of our fiscal year ended June 30, 2003 whose total
annual salary and bonus exceeded $100,000 for these periods, and (c) up to two
additional individuals, if any, for whom disclosure would have been provided
pursuant to (b) except that the individual(s) were not serving as our executive
officers at the end of our fiscal year ended June 30, 2003:
Summary Compensation Table
Annual compensation Long term compensation
-------------------------- ----------------------------------------------------
Awards Payouts
All
Restricted Securities other
Stock underlying LTIP compen-
Name & Salary Bonus Other Awards options/SARs payouts sation
Principal ------ ----- ----- ------ ------------ ------- ------
Position Year $ $ $ $ $ $
-------- ----
Christopher B.
Wood (1) 2003 225,000 - 500,000
2002 225,000 -
2001 180,000 - 1,500,000
David P. Luci (2) 2003 205,200 25,000(3) 500,000
2002 - -
2001 - -
Hugh Griffith (4) 2003 180,000 20,000 300,000
2002 - -
2001 - -
Stuart Smith (5) 2003 - -
2002 150,000 - -
2001 150,000 - 500,000
--------------------------
(1) On April 30, 2001, Dr. Wood was granted options to purchase 1,500,000
shares of our common stock. The options are immediately exercisable and
originally expired on April 30, 2004 but have been extended to April 30,
2006.
(2) On July 22, 2002, Mr. Luci was granted options to purchase 380,000 shares
of our common stock. On March 31, 2003, in connection with the execution
of an employment agreement between the Company and Mr. Luci, these options
were cancelled and the Company issued options to purchase 500,000 shares
of common stock at a then-current fair market value. Of these options,
options to purchase 170,000 shares of our common stock are immediately
exercisable and, subject to certain circumstances, options to purchase
110,000 shares of common stock vest and become exercisable on each of the
first, second and third anniversaries of March 31, 2003, the grant date.
(3) The annual bonus of $57,000 was prorated for the portion of calendar year
2002 within which Mr. Luci was employed by the Company.
(4) On October 22, 2003, Mr. Griffith was granted options to purchase 300,000
shares of our common stock at a then-current fair market value. Of these
options, options to purchase 100,000 shares of our common stock vest and
become exercisable, subject to
-15-
certain circumstances, on each of the first, second and third
anniversaries of October 22, 2002, the grant date.
(5) On April 30, 2001, Mr. Smith was granted options to purchase 500,000
shares of our common stock. The options are immediately exercisable and
originally expired on April 30, 2004 but have been extended to April 30,
2006. On September 30, 2002, Stuart Smith resigned from his position as
Senior Vice President of the Company and his employment agreement was
terminated.
EMPLOYMENT AGREEMENTS
We have entered into employment agreements with each of our principal
executive officers. Pursuant to these agreements, our executive officers agree
to devote all or a substantial portion of their business and professional time
efforts to our business as executive officers. The employment agreements provide
for certain compensation packages, which include bonuses and other incentive
compensation. The agreements also contain covenants restricting the employees
from competing with us and our business and prohibiting them from disclosing
confidential information about us and our business.
On September 1, 1999, we entered into an employment agreement with
Christopher B. Wood, M.D. under which he serves as our Chairman and Chief
Executive Officer. The initial term of Dr. Wood's employment agreement is two
years with automatic one-year extensions thereafter unless either party gives
written notice to the contrary. On December 31, 2002, we entered into a new
employment agreement with Dr. Wood, under which he continues to serve as our
Chairman and Chief Executive Officer. Under this contract, the term is one year,
with automatic one-year extensions thereafter unless either party provides
written notice to the contrary. Dr. Wood's new employment agreement provides for
an initial base salary of $225,000, a bonus as determined by the Board of
Directors, health insurance and other benefits currently or in the future
provided to key employees of the Company. If Dr. Wood's employment is terminated
other than for cause or if he resigns for good reason or if a change of control
occurs, he will receive a lump sum payment in an amount equal to his then
current annual base salary and any and all unvested options will vest and
immediately become exercisable.
On January 1, 2000, we entered into an employment agreement with Stuart
Smith under which he serves as our Senior Vice President. The initial term of
Mr. Smith's employment agreement is two years, with automatic one-year
extensions thereafter unless either party gives written notice to the contrary.
Mr. Smith's agreement provides for an initial base salary of $150,000, a bonus
as determined by the board of directors, life insurance benefits equal to his
annual salary, health insurance and other benefits currently or in the future
provided to our key employees. On September 30, 2002, Mr. Smith resigned from
his position as Senior Vice President of the Company; his employment agreement
was terminated and the Company agreed to issue shares of its common stock to Mr.
Smith at the then current fair market value in satisfaction of all outstanding
obligations of the Company to Mr. Smith pursuant to the employment agreement.
On March 31, 2003, we entered into an employment agreement with David P.
Luci, pursuant to which he serves as our Director of Finance, General Counsel
and Corporate Secretary. The initial term of Mr. Luci's employment agreement is
one-year, with automatic one-year extensions thereafter unless either party
provides written notice to the contrary. If Mr. Luci's employment is terminated
other than for cause or if he resigns for good reason or if a change of control
occurs, he will receive a lump sum payment in an amount equal to 1.5 multiplied
by the sum of (i) his then current annual base salary plus (ii) his then average
annual bonus for the preceding two years and any and all unvested options will
vest and immediately become exercisable.
STOCK OPTIONS AND LONG TERM INCENTIVE PLANS
The following table sets forth information concerning option/SAR grants
in our fiscal year ended June 30, 2003 to all individuals serving as (a) our
chief executive officer, (b) each of our four other most highly compensated
executive officers (other than our chief executive officer) at the end of our
fiscal year ended June 30, 2003
-16-
whose total annual salary and bonus exceeded $100,000 for these periods, and (c)
up to two additional individuals, if any, for whom disclosure would have been
provided pursuant to (b) except that the individual(s) were not serving as our
executive officers at the end of our fiscal year ended June 30, 2003:
------------------------------------------------------------------------------------------------------
Option/SAR Grants in Last Fiscal Year
[Individual Grants]
------------------------------------------------------------------------------------------------------
Name Number of Percent of total Exercise or base Expiration Date
securities options/SARs price ($/Share)
underlying granted to
options/SARs employees in
granted (#) fiscal year
---------------------- ------------------- ------------------- -------------------- ------------------
Christopher B. Wood 500,000 36.5% $1.45 12/31/12
---------------------- ------------------- ------------------- -------------------- ------------------
David P. Luci 500,000 36.5% $0.74 3/31/13
---------------------- ------------------- ------------------- -------------------- ------------------
Hugh Griffith 300,000 21.9% $1.45 10/23/12
---------------------- ------------------- ------------------- -------------------- ------------------
There were no options/SARs exercised in our fiscal year ended June 30,
2003 by the named executive officers.
The following table shows the June 30, 2003 fiscal year-end value of the
stock options held by the Named Executive Officers.
Year End 2003 Option/SAR Values
Number of Securities
Underlying Unexercised Value of Unexercised In-the-Money
Options/SARs at Year End Options/SARs at Year End (1)
------------------------------------- --------------------------------------------
Name Exercisable Unexercisable Exercisable Unexercisable
---- ----------- ------------- ----------- -------------
Christopher B. Wood 1,500,000 500,000 $1,455,000 $385,000
170,000 330,000 $251,600 $448,400
David P. Luci
100,000 200,000 $77,000 $154,000
Hugh Griffith
----------------------------------
(1) Amounts shown reflect the excess of the market value of the underlying our
common stock at year end based upon the $2.22 per share closing price on June
30, 2003 over the exercise prices for the stock options. The actual value, if
any, an executive may realize is dependent upon the amount by which the market
price of our common stock exceeds the exercise price when the stock options are
exercised.
-17-
Equity Compensation Plan Information
The following table provides information about the securities authorized
for issuance under the Company's equity compensation plans as of June 30, 2003:
Number of
securities to Number of securities
be issued upon remaining available
exercise of Weighted-average for future issuance
outstanding exercise price under equity
options, of outstanding compensation plans
warrants and options, warrants (excluding securities
rights and rights reflected in column (a))
(a) (b) (c)
------------------------------ -------------------- --------------------- --------------------------
Equity compensation plans
approved by security
holders (1) -- -- --
Equity compensation plans
not approved by security
holders 6,378,333 $1.30 --
Total 6,378,333 $1.30 --
(1) At June 30, 3002, the Company had no equity compensation plans approved by
security holders.
COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT
Section 16(a) of the Exchange Act requires Bioenvision's directors and
executive officers, and persons who own more than 10% of the outstanding equity
securities of Bioenvision, to file initial reports of beneficial ownership and
reports of changes in beneficial ownership of equity securities with the SEC and
any national securities exchange on which equity securities are listed. These
persons are required by SEC regulations to furnish Bioenvision with copies of
all Section 16(a) forms they file.
Based upon a review of filings made with the SEC and Bioenvision's
records, Bioenvision believes that certain of its directors, executive officers
or holders of more than 10% of the outstanding shares of common stock have not
filed on a timely basis the reports required by Section 16(a) of the Exchange
Act during, or with respect to, the year ended June 30, 2003.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information regarding the
beneficial ownership of common stock, as of November 10, 2003, by (i) each
person whom we know to beneficially own 5% or more of the common stock, (ii)
each of our directors, (iii) each person listed on the Summary Compensation
Table set forth under "Executive Compensation" and (iv) all of our directors and
executive officers. The number of shares of common stock beneficially owned by
each stockholder is determined in accordance with the rules of the Commission
and does not necessarily indicate beneficial ownership for any other
-18-
purpose. Under these rules, beneficial ownership includes those shares of common
stock over which the stockholder exercises sole or shared voting or investment
power. The percentage ownership of the common stock, however, is based on the
assumption, expressly required by the rules of the Commission, that only the
person or entity whose ownership is being reported has converted or exercised
common stock equivalents into shares of common stock; that is, shares underlying
common stock equivalents are not included in calculations in the table below for
any other purpose, including for the purpose of calculating the number of shares
outstanding generally. The table below does not reflect the right of ILEX to
purchase from us $1.0 million of our common stock at the then applicable market
price within 30 days of the completion of the Phase II trial for Clofarabine,
and an additional $2.0 million of our common stock at the then applicable market
price within 30 days of submittal to the FDA of the NDA for Clofarabine.
BENEFICIAL OWNERSHIP CURRENT PERCENTAGE OF
NAME OF STOCK CLASS (1)
Perseus-Soros Biopharmaceutical
Fund, LP (2)
888 Seventh Avenue, 29th Floor
New York, New York 10106.................... 9,000,000 33.02%
OrbiMed Advisors Inc. (3)
767 Third Avenue, 30th Floor
New York, New York 10017.................... 3,000,000 14.02%
Merlin Biomed Private Equity Fund LP (4)
230 Park Avenue, Suite 928
New York, New York 10169.................... 1,000,002 5.19%
DWS Investment GmbH (5)
Gruneburgweg M3-M5
60323 Frankfurt
Germany..................................... 1,299,999 6.65%
SCO Capital Partners LLC (6)
1285 Avenue of the Americas, 35th Floor
New York, New York 10019.................... 7,409,946 36.07%
Kevin Leech (7)
The Old Chapel
Sacre Couer
Rouge Boullion
St Helier
Jersey, Channel Islands..................... 1,900,000 10.13%
Bioaccelerate, Inc. (8)
PO Box 3175
Road Town
Tortolla
British Virgin Islands...................... 1,227,272 6.54%
Christopher B. Wood, M.D. (9)
c/o Bioenvision, Inc.
509 Madison Avenue, Suite 404
New York, New York 10022.................... 3,957,342 20.03%
Stuart Smith (10)
c/o Bioenvision, Inc.
509 Madison Avenue, Suite 404
New York, New York 10022.................... 700,000 3.73%
-19-
David P. Luci (11)
c/o Bioenvision, Inc.
509 Madison Avenue, Suite 404
New York, New York 10022........................... 170,000 *
Hugh Griffith
c/o Bioenvision, Inc.
509 Madison Avenue, Suite 404
New York, New York 10022
0 *
Ian Abercrombie
c/o Bioenvision
509 Madison Avenue, Suite 404
New York, New York 10022 0 *
Thomas Scott Nelson (12)
c/o Bioenvision, Inc.
509 Madison Avenue, Suite 404
New York, New York 10022.................... 287,523 1.56%
Jeffrey B. Davis (13)
1285 Avenue of the Americas, 35th Floor
New York, New York 10019................... 749,243 4.00%
Steven A. Elms
888 Seventh Avenue, 29th Floor
New York, New York 10106.................... 0 *
Andrew N. Schiff, M.D.
888 Seventh Avenue, 29th Floor
New York, New York 10106.................... 0 *
All Executive Officers and Directors as a
group (eight persons) (14).................. 6,364,108 25.35%
----------------
* Represents holdings of less than one percent (1%).
(1) Based on a total of 17,417,739 shares of common stock outstanding as of
September 15, 2002.
(2) Includes 3,000,000 shares of Series A Preferred Stock currently convertible
into 6,000,000 shares of common stock at a conversion price of $1.50 and a
warrant to purchase 3,000,000 shares of common stock exercisable at $2.00 per
share for five years from May 8, 2002. Based upon information contained in its
report on Schedule 13D filed with the Commission on May 20, 2002, Perseus-Soros
BioPharmaceutical Fund, L.P. reported that Perseus-Soros BioPharmaceutical Fund,
L.P. and Perseus-Soros Partners may be deemed to have sole power to direct the
voting and disposition of the 9,000,000 shares of common stock. By virtue of the
relationships between and among Perseus-Soros BioPharmaceutical Fund, L.P.,
Perseus-Soros Partners, LLC, Perseus BioTech Fund Partners, LLC, SFM
Participation, L.P., SFM AH, Inc., Frank H. Pearl, George Soros, Soros Fund
Management LLC, Perseus EC, LLC, Perseuspur, LLC, each of such Perseus entities,
other than Perseus-Soros BioPharmaceutical Fund, L.P. and Perseus-Soros
Partners, may be deemed to share the power to direct the voting and disposition
of the 9,000,000 shares of common stock.
(3) Includes 669,964 shares of Series A Preferred Stock currently convertible
into 1,339,928 shares of common stock at a conversion price of $1.50 and a
warrant to purchase 669,964 shares of common stock exercisable at $2.00 per
share for five years from May 16, 2002, both of which are held by Caduceus
Private Investments, LP; 13,945
-20-
shares of Series A Preferred Stock currently convertible into 27,980 shares of
common stock at a conversion price of $1.50 and a warrant to purchase 13,945
shares of common stock exercisable at $2.00 per share for five years from May
16, 2002, both of which are held by OrbiMed Associates LLC; and 316,091 shares
of Series A Preferred Stock currently convertible into 632,182 shares of common
stock at a conversion price of $1.50 and a warrant to purchase 316,091 shares of
common stock exercisable at $2.00 per share for five years from May 16, 2002,
both of which are held by PW Juniper Crossover Fund, L.L.C. Based upon
information contained in its report on Schedule 13G filed with the Commission on
June 21, 2002, OrbiMed Advisors Inc., OrbiMed Advisors LLC, OrbiMed Capital LLC
and Samuel D. Isaly reported that they share the power to direct the voting and
disposition of the 3,000,000 shares of common stock.
(4) Includes 333,334 shares of Series A Preferred Stock currently convertible
into 666,668 shares of common stock at a conversion price of $1.50 and a warrant
to purchase 333,334 shares of common stock exercisable at $2.00 per share for
five years from May 8, 2002. Based upon information contained in its report on
Schedule 13G filed with the Commission on June 28, 2002, Merlin BioMed Private
Equity Fund, L.P. reported that it shares the power to direct the voting and
disposition of the 1,000,002 shares of common stock with Merlin BioMed Private
Equity, LLC, its general partner and Dominique Semon, who is the sole managing
member of the general partner.
(5) Includes 433,333 shares of Series A Preferred Stock currently convertible
into 866,666 shares of common stock at a conversion price of $1.50 and a warrant
to purchase 433,333 shares of common stock exercisable at $2.00 per share for
five years from May 14, 2002.
(6) Includes a warrant to purchase 1,200,000 shares of common stock exercisable
at $1.25 per share for five years from November 16, 2001; a warrant to purchase
688,333 shares of common stock exercisable at $1.50 per share for five years
from May 8, 2002; a warrant to purchase 100,000 shares of common stock
exercisable at $1.25 per share Financial Group LLC for five years from November
16, 2001 held by SCO; a warrant to purchase 150,000 shares of common stock
exercisable at $1.25 per share for five years from November 16, 2001 held by the
Sophie C. Rouhandeh Trust; and a warrant to purchase 150,000 shares of common
stock exercisable at $1.25 per share for five years from November 16, 2001 held
by the Chloe H. Rouhandeh Trust. Steven H. Rouhandeh, in his capacity as
President of SCO Capital Partners LLC, has investment power and voting power
with respect to these shares, but disclaims any beneficial ownership thereof.
(7) These shares are owned of record by Phoenix Ventures Limited, a Channel
Islands (Jersey) corporation, which, to our knowledge, is wholly-owned by Kevin
Leech. These shares include 500,000 options which are exercisable at $1.25 per
share for the benefit of Phoenix Ventures Limited.
(8) Bioaccelerate, Inc. is a BVI corporation, owned of record by several private
investors and includes options to acquire 500,000 shares of the common stock
which are exercisable at $1.25 per share for five years from April 30, 2001.
Barbara Platts, in her capacity as Managing Director of Bioaccelerate, Inc., has
investment power and voting power with respect to these shares, but disclaims
any beneficial ownership thereof.
(9) Includes 318,750 shares of common stock owned by Julie Wood, Dr. Wood's
spouse, as to which Dr. Wood disclaims any beneficial interest, and 1,500,000
options which are exercisable at $1.25 for five years from April 30, 2001.
(10)Includes options to acquire 500,000 shares of the common stock which are
exercisable at $1.25 per share for five years from April 30, 2001.
(11)Includes options to acquire 170,000 shares of common stock which are
exercisable at $0.735 per share from March 31, 2003.
-21-
(12)Includes options to acquire 200,000 shares of the common stock which are
exercisable at $1.25 per share for five years from April 30, 2001.
(13)Includes a warrant to purchase 250,000 shares of common stock exercisable at
$1.50 per share for five years from May 8, 2002. Mr. Davis is the President of
SCO Financial Group LLC, an affiliate of SCO Capital Partners LLC. Mr. Davis
disclaims beneficial ownership of all shares of common stock deemed beneficially
owned by SCO Capital Partners LLC.
(14)Includes shares of common stock owned by Christopher B. Wood,David P. Luci,
Hugh Griffith, Ian Abercrombie, Thomas Nelson, Jeffrey Davis, Steven A. Elms and
Andrew Schiff, M.D. Also includes (a) 318,750 shares of common stock owned by
Julie Wood, Dr. Wood's spouse, as to which Dr. Wood disclaims any beneficial
interest, (b) Christopher Wood's options to acquire 1,500,000 shares of common
stock,(c) David Luci's options to acquire 170,000 shares of common stock, (d)
Thomas Nelson's options to acquire 200,000 shares of common stock and (e)
Jeffrey B. Davis' warrant to purchase 250,000 shares of common stock.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.
In August 2001 Bioenvision issued 208,333 shares at the rate of $1.25
per share in lieu of salary and consulting fees as follows: Christopher B. Wood,
98,684 shares; Thomas Nelson, 27,412 shares; and Stuart Smith, 82,237 shares.
In August 2001, we obtained a $1 million line of credit facility, which
expires in September 2002, from Jano Holdings Limited, one of our stockholders.
This credit facility was terminated in May 2002.
In October 2001, we issued 134,035 shares of common stock to officers as
payment for salaries accrued to September 30, 2001.
On November 16, 2001, we entered into an engagement letter with SCO
Capital, pursuant to which SCO would act as our financial advisor. In connection
with the engagement letter, we issued a warrant to purchase 100,000 shares of
common stock at an exercise price of $1.25 per share, subject to certain
anti-dilution adjustments. The warrants expire five years from the date of
issuance. Pursuant to this engagement letter, among other things, SCO Capital
performs investor relations services for the Company and earns a monthly fee of
$9,000 per month in connection therewith.
On November 16, 2001, in connection with securing a credit facility with
SCO Capital, we issued warrants to purchase 1,500,000 shares of our common stock
at a strike price of $1.25 per share, subject to certain anti-dilution
adjustments. The warrants expire five years from the date of issuance. The
credit facility with SCO Capital was terminated in May 2002.
On February 5, 2002, we completed the acquisition of Pathagon Inc. In
connection therewith, on February 1, 2002 we issued 7,000,000 shares of common
stock to the former stockholders of Pathagon Inc.
In May 2002, we completed a private placement pursuant to which we
issued an aggregate of 5,916,666 shares of Series A convertible participating
preferred stock for $3.00 per share and warrants to purchase an aggregate of
5,916,666 shares of common stock. An affiliate of SCO Capital Partners LLC, one
of our stockholders, served as financial advisor to the Company in connection
with this financing and earned a placement fee of approximately $1,200,000 in
connection therewith. This affiliate of SCO Capital Partners LLC continues to
serve as a financial advisor to the Company.
-22-
ANNUAL REPORT
The Company's annual report to stockholders is being concurrently
distributed to stockholders herewith.
OTHER MATTERS
The management of the Company does not know of any other matters to come
before the Annual Meeting. If, however, any other matters do come before the
Annual Meeting, it is the intention of the persons designated as proxies to vote
in accordance with their discretion on such matters.
STOCKHOLDER PROPOSALS
Any Company stockholder who wishes to submit a stockholder proposal
pursuant to Rule 14a-8 under the Exchange Act for inclusion in the Company's
proxy statement and proxy card for the Company's 2004 annual meeting of
stockholders must submit the proposal to the Company's Secretary no later than
August 17, 2004. Such submissions should be delivered to the Company's principal
executive offices at 507 Madison Avenue, New York, New York 10022, Attention:
David P. Luci.
PROXY CARD
----------
BIOENVISION, INC.
-----------------
THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS OF BIOENVISION, INC. FOR THE
2003 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JANUARY 14, 2004.
The undersigned, as a stockholder of Bioenvision, Inc. (the "Company"), hereby
appoints Christopher B. Wood, M.D. and David P. Luci, and each of them, with
full power of substitution, as proxies to vote all shares of stock of the
Company which the undersigned is entitled to vote through the execution of a
proxy with respect to the 2003 Annual Meeting of Stockholders of the Company
(the "Annual Meeting") to be held at the American Stock Exchange, 86 Trinity
Place, New York, NY 10006, on January 14, 2003 at 12:00 p.m., local time, or any
adjournment or postponement thereof, and authorizes and instructs said proxies
to vote in the manner directed below.
HOLDERS OF SERIES A PREFERRED STOCK ONLY:
1. Amendment of Certificate of Incorporation: To amend our certificate of
incorporation to (i)increase the authorized number of shares of our common stock
from 50,000,000 to 70,000,000 and (ii)increase the authorized number of shares
of our preferred stock from 10,000,000 to 20,000,000.
FOR { } AGAINST { } ABSTAIN { }
2. 2003 Stock Incentive Plan: To approve the adoption of our 2003 Stock
Incentive Plan.
FOR { } AGAINST { } ABSTAIN { }
3. Election of Directors
FOR WITHHELD
{ } { }
Nominees:
Christopher B. Wood, M.D.
Jeffrey B. Davis
Thomas Scott Nelson, C.A.
Steven A. Elms
Andrew Schiff, M.D.
WITHHELD FOR: (Write that nominee's name in the space provided):________________
4. In their discretion, to transact any other business as may properly come
before the Annual Meeting.
-23-
HOLDERS OF COMMON STOCK ONLY:
1. Amendment of Certificate of Incorporation: To amend our certificate of
incorporation to (i)increase the authorized number of shares of our common stock
from 50,000,000 to 70,000,000 and (ii)increase the authorized number of shares
of our preferred stock from 10,000,000 to 20,000,000.
FOR { } AGAINST { } ABSTAIN { }
2. 2003 Stock Incentive Plan: To approve the adoption of our 2003 Stock
Incentive Plan.
FOR { } AGAINST { } ABSTAIN { }
3. Election of Directors
FOR WITHHELD
{ } { }
Nominees:
Christopher B. Wood, M.D.
Jeffrey B. Davis
Thomas Scott Nelson, C.A.
Steven A. Elms
Andrew Schiff, M.D.
WITHHELD FOR: (Write that nominee's name in the space provided):________________
4. In their discretion, to transact any other business as may properly come
before the Annual Meeting.
You may revoke or change your proxy at any time prior to its use at the Annual
Meeting by giving the Company written direction to revoke it, by giving the
Company a new proxy or by attending the Annual Meeting and voting in person.
Your attendance at the Annual Meeting will not by itself revoke a proxy given by
you. Written notice of revocation or subsequent proxy should be sent to
Bioenvision, Inc. 509 Madison Ave., Suite 404, New York, New York 10022,
Attention: David P. Luci, so as to be delivered at or before the taking of the
vote at the Annual Meeting.
(Continued and to be signed on the reverse side)
Returned proxy cards will be voted (1) as specified on the matters listed above;
(2) in accordance with the Board of Directors' recommendations where no
specification is made; and (3) in accordance with the judgment of the proxies on
any other matters that may properly come before the meeting. Please mark your
choice like this: x
The shares represented by this Proxy will be voted in the manner directed and,
if no instructions to the contrary are indicated, will be voted FOR the election
of the named nominees and approval of the other proposal set forth above.
The undersigned hereby acknowledges receipt of the notice of the Annual Meeting
and the proxy statement furnished therewith.
Print and sign your name below exactly as it appears hereon and date this card.
When signing as attorney, executor, administrator, trustee or guardian, please
give full title as such. Joint owners should each sign. If a corporation, please
sign in full corporate name by president or authorized officer. If a
partnership, please sign in partnership name by authorized person.
Date: ____________________________
----------------------------
Signature (title, if any)
----------------------------
Signature, if held jointly
ANNEX A
CERTIFICATE OF AMENDMENT
OF
CERTIFICATE OF INCORPORATION
OF
BIOENVISION, INC.
Pursuant to Section 242
of the General Corporation Law of
the State of Delaware
---------------------
Bioenvision Inc. (hereinafter called the "Corporation"), a corporation
duly organized and existing under and by virtue of the General Corporation Law
of the State of Delaware, does hereby certify as follows:
FIRST: That the Board of Directors of said Corporation (the "Board"),
pursuant to a written action in lieu of a meeting, as filed with the minutes of
the Board, duly adopted a resolution pursuant to Section 242 of the General
Corporation Law of the State of Delaware setting forth an amendment to the
Certificate of Incorporation of the Corporation and proposing and declaring said
amendment to be advisable. The resolution setting forth the amendment is as
follows:
RESOLVED, that the certificate of incorporation be amended to read as
follows:
"FOURTH. The total number of shares of all classes of capital
stock which the corporation shall have the authority to issue
is 90,000,000 shares consisting of: (1) 70,000,000 shares of
Common Stock, par value $0.00l per share and (2) 20,000,000
shares of Preferred Stock, par value $0.001 per share. The
Preferred Stock shall be issuable in one or more series with
such powers, designations, preferences, rights,
qualifications, limitations or restrictions as may be
determined in the board's sole discretion, with no further
authorization by stockholders required for the creation and
issuance thereof. When required by law and in accordance with
the provisions of Section 151 of the General Corporation Law
of the State of Delaware, the board shall have the express
authority to execute, acknowledge and file a certificate of
designations, preferences, rights, qualifications, limitations
or restrictions of the Preferred Stock."
IN WITNESS WHEREOF, Bioenvision, Inc. has caused this Certificate
to be signed by Christopher B. Wood, its Chairman and Chief Executive Officer,
this _____ day of ______, 2003.
Bioenvision, Inc.
By:___________________________________
Name: Christopher B. Wood
Title: Chairman and Chief Executive Officer
ANNEX B
BIOENVISION, INC.
2003 STOCK INCENTIVE PLAN
1. PURPOSE.
The Plan is intended to provide incentives to key Employees,
directors and consultants of the Corporation, to encourage their proprietary
interest in the Corporation, and to attract new Employees, directors and
consultants with outstanding qualifications through providing select current and
prospective key Employees, directors and consultants of the Corporation with the
opportunity to acquire Shares.
2. DEFINITIONS.
Whenever the following terms are used in this Plan, they shall
have the meaning specified below unless the context clearly indicates otherwise.
(a) "Act" shall mean the Securities Act of 1933, as amended.
(b) "Administrator" shall mean the Board or the Compensation
Committee, whichever shall be administering the Plan from time to
time in the discretion of the Board, as described in Section 4 of
the Plan.
(c) "Award" shall mean any award made pursuant to this Plan,
including Options, Restricted Shares and Performance Units.
(d) "Award Agreement" shall mean any written document setting forth
the terms and conditions of an Award, as prescribed by the
Administrator.
(e) "Board" shall mean the Board of Directors of the Corporation.
(f) "Cause" in respect of a Participant shall mean dishonesty, fraud,
misconduct, unauthorized use or disclosure of confidential
information or trade secrets, conviction or confession of a crime
punishable by law (except misdemeanor violations), or engaging in
practices contrary to stock "insider trading" policies of the
Corporation, by such Participant, in each case as determined by
the Administrator, with such determination to be conclusive and
binding on such affected Participant and all other persons.
(g) "Change of Control" shall mean the occurrence of any of the
following: (i) the acquisition, directly or indirectly, by any
individual or entity or group (as such term is used in Section
13(d)(3) of the Exchange Act) of beneficial ownership (as defined
in Rule 13d-3 under the Exchange Act, except that such individual
or entity shall be deemed to have beneficial ownership of all
shares that any such individual or entity has the right to
acquire without the happening or failure to happen of a material
condition or contingency, other than the passage of time) of more
than 50% of the aggregate outstanding voting power of capital
stock of the Corporation in respect of the general power to elect
directors; or (ii) (A) the Corporation consolidates with or
merges into another entity or sells all or substantially all of
its assets to any individual or entity, or (B) any corporation
consolidates with or merges into the Corporation, which in either
event (A) or (B) is pursuant to a transaction in which the
holders of the Corporation's voting capital stock in respect of
the general power to elect directors immediately prior to such
transaction do not own, immediately following such transaction,
at least a majority of the voting
capital stock in respect of the general power to elect directors
of the surviving corporation or the person or entity which owns
the assets so sold.
(h) "Code" shall mean the Internal Revenue Code of 1986, as amended.
(i) "Compensation Committee" shall mean the compensation committee of
the Board.
(j) "Common Stock" shall mean the Common Stock, par value $.001 per
share, of the Corporation.
(k) "Corporation" shall mean Bioenvision, Inc., a Delaware
corporation, or any successor hereunder.
(l) "Disability" shall mean the condition of a Participant who is
unable to engage in any substantial gainful activity by reason of
any medically determinable physical or mental impairment which
can be expected to result in death or which has lasted or can be
expected to last for a continuous period of not less than twelve
(12) months. The determination of whether a Participant is
disabled shall be made in the Administrator's sole discretion.
(m) "Employee" shall mean an individual whom the Corporation or a
Subsidiary classifies as an employee for employment and payroll
tax purposes.
(n) "Exchange Act" shall mean the Securities Exchange Act of 1934, as
amended.
(o) "Exercise Price" shall mean the price per Share of Common Stock,
determined by the Administrator, at which an Option may be
exercised.
(p) "Fair Market Value" shall mean shall mean (i) if the Shares are
traded on a national securities exchange, the closing price for
such Shares on the day immediately preceding the date of
determination or if there is no closing price on such date, the
last preceding closing price, (ii) if the Shares are not traded
on a national securities exchange, the mean of the high bid and
ask quotes of such Shares as reported in the NASDAQ/NMS reports
or the National Quotation Bureau Inc.'s pink sheets or in the
NASD Bulletin Board on the day immediately preceding the date of
determination or if there were no high bid and ask quotes on such
date, the last preceding day that there were, and (iii) if
neither (i) or (ii) are applicable, as determined in good faith
by the Administrator.
(q) "Good Reason" in respect of a Participant shall mean the
occurrence of any of the following events or conditions first
occurring on or following a Change of Control:
A change in the Participant's status, title, position or
responsibilities (including reporting responsibilities) that
represents a substantial reduction of the status, title, position
or responsibilities in respect of the Corporation's business as
in effect immediately prior thereto; the assignment to the
Participant of substantial duties or responsibilities that are
inconsistent with such status, title, position or
responsibilities; or any removal of the Participant from or
failure to reappoint or reelect the Participant to any of such
positions, except in connection with the termination of the
Participant's service for Cause, for Disability or as a result of
his or her death, or by the Participant other than for Good
Reason;
A reduction in the Participant's annual base salary;
The Corporation's requiring the Participant (without the
Participant's consent) to be based at any place outside a 35-mile
radius of his or her
place of employment immediately prior to a Change of Control,
except for reasonably required travel on the Corporation's
business that is not materially greater than such travel
requirements prior to such Change of Control;
The Corporation's failure to (i) continue in effect any material
compensation or benefit plan (or a reasonable replacement
therefor) in which the Participant was participating immediately
prior to a Change of Control, including, but not limited to the
Plan, or (ii) provide the Participant with compensation and
benefits at least equal (in terms of benefit levels and/or reward
opportunities) to those provided for under each employee benefit
plan, program and practice as in effect immediately prior to a
Change of Control (or as in effect following the Change of
Control, if greater); or
Any material breach by the Corporation of any provision of the
Plan.
(r) "Incentive Stock Option" shall mean an option described in
Section 422(b) of the Code.
(s) "Non-Employee Director" shall have the meaning assigned to this
phrase in Rule 16b-3 of the Securities and Exchange Commission
adopted under the Exchange Act.
(t) "Nonstatutory Stock Option" shall mean an option not described in
Section 422(b) or 423(b) of the Code.
(u) "Option" shall mean any stock option granted pursuant to the
Plan.
(v) "Option Profit" shall mean the amount (not less than zero) by
which the Fair Market Value of a share of Common Stock subject to
a Nonstatutory Stock Option on the date of a Participant's
exercise of a Nonstatutory Stock Option exceeds the exercise
price of such Nonstatutory Stock Option.
(w) "Participant" shall mean any person who receives an Award
pursuant to Sections 5(a), 8(a), 9(a) or 9(b) hereof.
(x) "Performance Units" shall mean Awards granted pursuant to Section
9(a) or 9(b) hereof.
(y) "Plan" shall mean this Bioenvision, Inc. 2003 Stock Incentive
Plan, as it may be amended from time to time.
(z) "Purchase Price" shall mean the Exercise Price times the number
of Shares with respect to which an Option is exercised.
(aa) "Restricted Shares" shall mean Shares awarded pursuant to Section
8 of this Plan.
(bb) "Retirement" shall mean the voluntary cessation of employment by
an Employee at such time as may be specified in the then current
personnel policies of the Corporation, in the sole discretion of
the Administrator or, in lieu thereof, upon the attainment of age
sixty-five (65) and the completion of not less than twenty (20)
years of service with the Corporation or a Subsidiary.
(cc) "Share" shall mean one (1) share of Common Stock, adjusted in
accordance with Section 11 of the Plan (if applicable).
(dd) "Subsidiary" shall mean any subsidiary corporation as defined in
Section 424(f) of the Code, and shall include any entity as to
which the Corporation directly or indirectly owns more than a
forty percent (40%) interest.
3. EFFECTIVE DATE.
The Plan was adopted by the Board and became effective immediately on
November 17, 2003, subject to the approval of the Corporation's stockholders
pursuant to Section 17 of the Plan.
4. ADMINISTRATION.
The Plan shall be administered, in the discretion of the Board
from time to time, by the Board or by the Compensation Committee. The
Administrator shall from time to time at its discretion select the Participants
who are to be granted Awards, determine the form of Award Agreements, determine
the number of Shares to be subject to Awards to be granted to each Participant,
designate an Award of Options as Incentive Stock Options or Nonstatutory Stock
Options and determine to what extent the Award shall be transferable. The
interpretation and construction by the Administrator of any provisions of the
Plan or of any Award granted thereunder shall be final. No member of the
Administrator shall be liable for any action or determination made in good faith
with respect to the Plan or any Award granted thereunder.
So long as the Common Stock is registered under Section 12 of the
Exchange Act, then notwithstanding the first or second sentences of the
immediately preceding paragraph, selection of officers and directors for
participation and decisions concerning the timing, pricing and amount of an
Award shall be made solely by the Board, or by the Compensation Committee, each
of the members of which shall be a Non-Employee Director. If the Compensation
Committee grants an Award to a person subject to Code Section 162(m), each
member of the Compensation Committee shall be an "outside director" within the
meaning of that section.
5. PARTICIPATION.
(a) Eligibility.
The Participants shall be such Employees (who may be officers,
whether or not they are directors) and directors of or consultants to the
Corporation or a Subsidiary (whether or not they are Employees) as the
Administrator may select subject to the terms and conditions of Section 5(b)
below; provided that directors or consultants who are not also Employees shall
not be eligible to receive Incentive Stock Options.
(b) Ten-Percent Stockholders.
A Participant who owns more than ten percent (10%) of the total
combined voting power of all classes of outstanding stock of the Corporation,
its parent or any of its Subsidiaries shall not be eligible to receive an
Incentive Stock Option unless (i) the Exercise Price of the Shares subject to
such Option is at least one hundred ten percent (110%) of the Fair Market Value
of such Shares on the date of grant and (ii) such Option by its terms is not
exercisable after the expiration of five (5) years from the date of grant.
(c) Stock Ownership.
For purposes of Section 5(b) above, in determining stock
ownership, a Participant shall be considered as owning the stock owned, directly
or indirectly, by or for his or her brothers and sisters (by whole or half
blood), spouse, ancestors and lineal descendants. Stock owned, directly or
indirectly, by or for a corporation, partnership, estate or trust shall be
considered as being owned proportionately by or for its stockholders, partners
or beneficiaries. Stock with respect to which such
Participant holds an Option or any other option if (as of the time the Option or
such other option is granted) the terms of such Option or other option provide
that it will not be treated as an Incentive Stock Option, shall not be counted.
(d) Outstanding Stock
For purposes of Section 5(b) above, "outstanding stock" shall
include all stock actually issued and outstanding immediately after the grant of
the Option to the Participant . "Outstanding stock" shall not include shares
authorized for issuance under outstanding Options held by the Participant or by
any other person.
6. STOCK.
The stock subject to Awards granted under the Plan shall be
Shares of the Corporation's authorized but unissued or reacquired Shares of
Common Stock. The aggregate number of Shares as to which Awards may be granted
shall be 3,000,000. Notwithstanding the foregoing, the maximum number of shares
of Common Stock for which Incentive Stock Options may be granted under the Plan
shall not exceed 3,000,000 shares of Common Stock, reduced by the sum of all
Shares previously issued pursuant to Incentive Stock Option Awards and by the
aggregate number of Shares of Common Stock subject to then-outstanding Incentive
Stock Options. For purposes of the limitations set forth in this Section, if any
portion of an Award is forfeited, canceled, reacquired by the Company, satisfied
without the issuance of Common Stock or otherwise terminated, the shares of
Common Stock underlying such portion of the Award shall be added back to the
shares of Common Stock available for issuance under the Plan. The limitations
established by this Section 6 shall be subject to adjustment in the manner
provided in Section 11 hereof upon the occurrence of an event specified therein.
7. TERMS AND CONDITIONS OF OPTIONS.
(a) Award Agreements.
Options shall be evidenced by written Award Agreements in such
form as the Administrator shall from time to time determine. Such agreements
need not be identical but shall comply with and be subject to the terms and
conditions set forth below. No Option shall be effective until the applicable
Award Agreement is executed by both parties thereto.
(b) Participant's Undertaking.
Each Participant shall agree to remain in the employ or service
of the Corporation and to render services for a period as shall be determined by
the Administrator, from the date of the granting of the Option, but such
agreement shall not impose upon the Corporation any obligation to retain the
Participant in their employ or service for any period.
(c) Number of Shares.
Each Option shall state the number of Shares to which it pertains
and shall provide for the adjustment thereof in accordance with the provisions
of Section 11 hereof.
(d) Exercise Price.
Each Option shall state the Exercise Price. The Exercise Price
shall not be less than the Fair Market Value on the date of grant and, in the
case of an Incentive Stock Option granted to a Participant described in Section
5(b) hereof, shall not be less than one hundred ten percent (110%) of the Fair
Market Value on the date of grant.
(e) Medium and Time of Payment.
The Purchase Price shall be payable in full in United States
dollars upon the exercise of the Option; provided, however, that if the
applicable Award Agreement so provides, or the Administrator, in its sole
discretion otherwise approves therefor, the Purchase Price may be paid by the
surrender of Shares in good form for transfer, owned by the person exercising
the Option for at least six months (subject to the Administrator's discretion to
waive this six-month requirement) and having a Fair Market Value on the date of
exercise equal to the Purchase Price, or in any combination of cash and Shares,
as long as the sum of the cash so paid and the Fair Market Value of the Shares
so surrendered equals the Purchase Price.
Payment of any tax withholding requirements may be made, in the
discretion of the Administrator, (i) in cash, (ii) by delivery of Shares
registered in the name of the Participant, or by the Corporation not issuing
such number of Shares subject to the Option, having a Fair Market Value at the
time of exercise equal to the amount to be withheld or (iii) any combination of
(i) and (ii) above. If the Corporation is required to register under Section
207.3 of Regulation G of the Board of Governors of the Federal Reserve System
(Title 12 Code of Federal Regulations Part 207), then so long as such
registration is in effect, the credit extended by the Corporation to a
Participant for the purpose of paying the Purchase Price shall conform to the
requirements of such Regulation G.
Upon a duly made deferral election by a Participant eligible to
participate under the Corporation's Deferred Compensation Plan, Shares otherwise
issuable to the Participant upon the exercise of a Nonstatutory Stock Option and
payment of the Purchase Price by the surrender of Shares (or by the payment of
cash if an Award Agreement so provides or if the Administrator exercises its
discretion to accept cash) in accordance with the first paragraph of this
Section 7(e), will not be delivered to the Participant. In lieu of delivery of
such Shares, the Common Stock Account (as defined in the Corporation's Deferred
Compensation Plan) of the Participant maintained pursuant to the Corporation's
Deferred Compensation Plan shall be credited with a number of stock units having
a value, calculated pursuant to such plan, equal to the Option Profit associated
with the exercised Nonstatutory Stock Option. Such deferral of Option Profit
under the Corporation's Deferred Compensation Plan is available to Participants
only if the Shares surrendered in payment of the Purchase Price upon the
exercise of a Nonstatutory Stock Option have been held by the Participant for at
least six months (or by the payment of cash if an Award Agreement so provides or
if the Administrator exercises its discretion to accept cash).
(f) Term of Options.
Each Option shall state the time or times when all or part
thereof becomes exercisable. No Option shall be exercisable after the expiration
of ten (10) years (or less, in the discretion of the Administrator) from the
date it was granted, and no Incentive Stock Option granted to a Participant
described in Section 5(b) hereof shall
be exercisable after the expiration of five (5) years (or less, in the
discretion of the Administrator) from the date it was granted.
(g) Cessation of Service (Except by Death, Disability or Retirement).
Except as otherwise provided in this Section 7, an Option may
only be exercised by Participants who have remained continuously in service as
an Employee, director or consultant with the Corporation since the date of grant
of the Option. If a Participant ceases to be an Employee, director or consultant
for any reason other than his or her death, Disability or Retirement, such
Participant shall have the right, subject to the restrictions referred to in
Section 7(f) above, to exercise the Option at any time within ninety (90) days
(or such shorter period as the Administrator may determine in an Award
Agreement) after cessation of service, but, except as otherwise provided in the
applicable Award Agreement, only to the extent that, at the date of cessation of
service, the Participant's right to exercise such Option had accrued pursuant to
the terms of the applicable Award Agreement and had not previously been
exercised. The foregoing notwithstanding: (i) unless otherwise provided in an
Award Agreement or in the sole discretion of the Administrator, the Option shall
cease to be exercisable on the date of such cessation of service if such
cessation arises by reason of termination for Cause; and (ii) an Award Agreement
may provide that the Option shall cease to be exercisable on the date of such
cessation of service if the Participant following cessation becomes an employee,
director or consultant of a person or entity that the Administrator, in its sole
discretion, determines is in direct competition with the Corporation or a
Subsidiary.
For purposes of this Section 7(g) the service relationship shall
be treated as continuing intact while the Participant is on military leave, sick
leave or other bona fide leave of absence (to be determined in the sole
discretion of the Administrator). The foregoing notwithstanding, service shall
not be deemed to continue beyond the ninetieth (90th) day after the Participant
ceased active service, unless the Participant's reemployment rights are
guaranteed by statute or by contract or the Administrator determines in its
discretion that the Participant's service shall be treated as continuing for a
term stated in writing.
(h) Death of Participant.
If a Participant dies while a Participant, or after ceasing to be
a Participant but during the period in which he or she could have exercised the
Option under this Section 7, and has not fully exercised the Option, then the
Option may be exercised in full, subject to the restrictions referred to in
Section 7(f) above, at any time within twelve (12) months (or such shorter
period as the Administrator may determine) after the Participant's death by the
executor or administrator of his or her estate or by any person or persons who
have acquired the Option directly from the Participant by bequest or
inheritance, but, except as otherwise provided in the applicable option
agreement, only to the extent that, at the date or death, the Participant's
right to exercise such Option had accrued and had not been forfeited pursuant to
the terms of the applicable Award Agreement and had not previously been
exercised.
(i) Disability of Participant.
If a Participant ceases to be an Employee, director or consultant
by reason of Disability, such Participant shall have the right, subject to the
restrictions referred to in Section 7(f) above, to exercise the Option at any
time within twelve (12) months (or such shorter period as the Administrator may
determine) after such cessation of service, but, except as provided in the
applicable Award Agreement, only to the extent that, at the date of such
cessation of service, the Participant's right to exercise such Option had
accrued pursuant to the terms of the applicable Award Agreement and had not
previously been exercised.
(j) Retirement of Participant.
If a Participant ceases to be an Employee by reason of
Retirement, such Participant shall have the right, subject to the restrictions
referred to in Section 7(f) above, to exercise the Option at any time within
ninety (90) days (or such longer or shorter period as the Administrator may
determine) after cessation of employment, but only to the extent that, at the
date of cessation of employment, the Participant's right to exercise such Option
had accrued pursuant to the terms of the applicable option agreement and had not
previously been exercised.
(k) Limitation on Incentive Stock Options
If the aggregate Fair Market Value (determined as of the date an
Option is granted) of the stock with respect to which Incentive Stock Options
are exercisable for the first time by any Participant during any calendar year
under this Plan and all other plans maintained by the Corporation, its parent or
its Subsidiaries, exceeds $100,000, the Option shall be treated as a
Nonstatutory Stock Option with respect to the stock having an aggregate Fair
Market Value exceeding $100,000.
(l) Other Provisions.
The Award Agreements authorized under the Plan may contain such
other provisions not inconsistent with the terms of the Plan (including, without
limitation, restrictions upon the exercise of the Option or the transfer of
Shares of stock following exercise of the Option) as the Administrator shall
deem advisable.
8. Restricted Share Awards
(a) Grants.
The Administrator shall have the discretion to grant Restricted
Shares to Participants. As promptly as practicable after a determination is made
that an Award of Restricted Shares is to be made, the Administrator shall notify
the Participant in writing of the grant of the Award, the number of Shares
covered by the Award, and the terms upon which the Shares subject to the Award
may be earned. The date on which the Administrator so notifies the Participant
shall be considered the date of grant of the Restricted Shares. The
Administrator shall maintain records as to all grants of Restricted Shares under
the Plan.
(b) Earning Shares.
Each Award Agreement for Restricted Shares shall state the time
or times, and the conditions or circumstances under which, all or part of the
Restricted Shares shall be earned and become nonforfeitable by a Participant.
(c) Accrual of Dividends.
Unless otherwise provided in an Award Agreement, on the last day
of each fiscal year of the Corporation, the Administrator shall credit to the
Participant's Restricted Share account under the Plan a number of Restricted
Shares having a Fair Market Value, on that date, equal to the sum of any cash
and stock dividends paid on Restricted Shares previously credited to the
Participant's account during such fiscal year. The Administrator shall hold each
Participant's Restricted Shares until distribution is required pursuant to
subsection (d) hereof.
(d) Distribution Of Restricted Shares.
Timing of Distributions; General Rule. Except as otherwise
expressly stated in this Plan, the Administrator shall distribute Restricted
Shares and any Restricted Shares attributable to accumulated cash or stock
dividends thereon to the Participant or his or her beneficiary, as the case may
be, as soon as practicable after they have been earned. No fractional shares
shall be distributed.
Form of Distribution. The Administrator shall distribute all
Restricted Shares, together with any Shares representing dividends, in the form
of Common Stock. One Share shall be given for each Restricted Share earned.
9. PERFORMANCE UNITS
(a) Performance Units. A Performance Unit is an Award denominated
in cash, the amount of which may be based on the achievement of specific goals
with respect to Corporation, Subsidiary or individual performance over a
specified period of time. The maximum amount of such compensation that may be
paid to any one Participant with respect to any one Performance Period
(hereinafter defined) shall be $50,000. Performance Units may be settled in
Shares (based on their Fair Market Value at the time of settlement, unless an
Award Agreement provides otherwise) or cash or both, and may be awarded by the
Administrator to Employees, directors or consultants to the Corporation or its
Subsidiaries.
(b) Performance Compensation Awards.
(1) The Administrator may, at the time of grant of a
Performance Unit or Restricted Share Award, designate such Award as a
"Performance Compensation Award" in order that such Award constitutes qualified
performance-based compensation under Code Section 162(m), in which event the
Administrator shall have the power to grant such Awards upon terms and
conditions that qualify such awards as "qualified performance-based
compensation" within the meaning of Code Section 162(m). With respect to each
such Performance Compensation Award, the Administrator shall establish, in
writing, a Performance Period, Performance Measure(s) (hereinafter defined), and
Performance Formula(s) (hereinafter defined). Once established for a Performance
Period, such items shall not be amended or otherwise modified to the extent such
amendment or modification would cause the compensation payable pursuant to the
Award to fail to constitute qualified performance-based compensation under Code
Section 162(m).
(2) A Participant shall be eligible to receive payment in
respect of a Performance Compensation Award only to the extent that the
Performance Measure(s) for such Award are achieved and the Performance Formula
as applied against such Performance Measure(s) determines that all or some
portion of such Participant's Award has been earned for the Performance Period.
As soon as practicable after the close of each Performance Period, the
Administrator shall review and certify in writing whether, and to what extent,
the Performance Measure(s) for the Performance Period have been achieved and, if
so, determine and certify in writing the amount of the Performance Compensation
Award to be paid to the Participant and, in so doing, may use negative
discretion to decrease, but not increase, the amount of the Award otherwise
payable to the Participant based upon such performance. The maximum Performance
Compensation Award for any one Participant for any one Performance Period shall
be 25,000 performance Restricted Shares or $50,000.
(c) Definitions.
(1) "Performance Formula" means, for a Performance Period,
one or more objective formulas or standards established by the Administrator for
purposes of determining whether or the extent to which an Award has been earned
based on the level of performance attained or to be attained with respect to one
or more Performance Measure(s). Performance Formulas may vary from Performance
Period to Performance Period and from Participant to Participant and may be
established on a stand-alone basis, in tandem or in the alternative.
(2) "Performance Measure" means one or more of the
following selected by the Administrator to measure Corporation, Subsidiary
and/or business unit performance for a Performance Period, whether in absolute
or relative terms (including, without limitation, terms relative to a peer group
or index): basic or diluted earnings
per share; sales or revenue; earnings before interest and taxes (in total or on
a per share basis); net income; returns on equity, assets, capital, revenue or
similar measure; economic value added; working capital; total stockholder
return; and product development, product market share, research, licensing,
litigation, human resources, information services, mergers, acquisitions, sales
of assets or subsidiaries. Each such measure shall be to the extent applicable,
determined in accordance with generally accepted accounting principles as
consistently applied by the Corporation (or such other standard applied by the
Administrator) and, if so determined by the Administrator, and in the case of a
Performance Compensation Award, to the extent permitted under Code Section
162(m), adjusted to omit the effects of extraordinary items, gain or loss on the
disposal of a business segment, unusual or infrequently occurring events and
transactions and cumulative effects of changes in accounting principles.
Performance Measures may vary from Performance Period to Performance Period and
from Participant to Participant and may be established on a stand-alone basis,
in tandem or in the alternative.
(3) "Performance Period" means one or more periods of time
(of not less than one fiscal year of the Corporation), as the Administrator may
designate, over which the attainment of one or more Performance Measure(s) will
be measured for the purpose of determining a Participant's rights in respect of
an Award.
10. TERM OF PLAN.
Awards may be granted pursuant to the Plan until the expiration
of the Plan ten years after the date (specified in Section 3) on which the Plan
received Board approval.
11. RECAPITALIZATIONS; CHANGE OF CONTROL.
(a) Adjustments in Respect of Recapitalizations and Other
Corporate Transactions.
The number of Shares covered by the Plan as provided in Section 6
hereof, the number of Shares covered by each outstanding Award and the Exercise
Price of Options shall be proportionately adjusted for any increase or decrease
in the number of issued Shares resulting from a subdivision or consolidation of
Shares or a stock split or the payment of a stock dividend (but only of Common
Stock) or any other increase or decrease in the number of issued Shares effected
without receipt of consideration by the Corporation.
If the Corporation shall merge with another corporation and the
Corporation is the surviving corporation in such merger and under the terms of
such merger the shares of Common Stock outstanding immediately prior to the
merger remain outstanding and unchanged, each outstanding Award shall continue
to apply to the Shares subject thereto and shall also pertain and apply to any
additional securities and other property, if any, to which a holder of the
number of Shares subject to the Award would have been entitled as a result of
the merger. If the Corporation sells all, or substantially all, of its assets,
or the Corporation merges (other than a merger of the type described in the
immediately preceding sentence) or consolidates with another corporation, this
Plan and each Award shall terminate; provided that in such event (i) each
Participant to whom no replacement Award has been tendered by the surviving or
acquiring corporation (or the parent corporation of the surviving or acquiring
corporation) in accordance with all of the terms of clause (ii) immediately
below, shall receive immediately before the effective date of such sale, merger
or consolidation, unrestricted Shares equal to the number of Restricted Shares
and the value of any Performance Units to which the Participant is then entitled
(regardless of any vesting condition), and shall have the right, for a period of
at least thirty days, until five days before the effective date of such sale,
merger or consolidation, to exercise, in whole or in part (in the discretion of
the Participant), any unexpired Option or Options issued to him or her, without
regard to the installment or vesting provisions of any option agreement, or (ii)
in its sole and absolute discretion, the surviving or
acquiring corporation (or the parent corporation of the surviving or acquiring
corporation) may, but shall not be obligated to, (I) tender to all Participants
with then Restricted Shares, an award of restricted shares of the surviving or
acquiring corporation (or the parent corporation of the surviving or acquiring
corporation), tender to all Participants with then Performance Units, an award
of performance units of the surviving or acquiring corporation (or the parent
corporation of the surviving or acquiring corporation), and tender to
Participants with outstanding Options under the Plan an option or options to
purchase shares of the surviving or acquiring corporation (or of the parent
corporation of the surviving or acquiring corporation), in which each new award
or awards contain such terms and provisions as shall be required substantially
to preserve the rights and benefits of all Awards then held by such Participants
or, (II) permit Participants to receive unrestricted Shares with respect to any
Restricted Shares (regardless of any vesting condition) immediately before the
effective date of the transaction, permit Participants to receive cash with
respect to value of any Performance Units (regardless of any vesting condition)
immediately before the effective date of the transaction, honor deferral
elections that Participants make pursuant to Section 8(e), and grant the choice
to all Participants with then outstanding Options of (A) exercising the Options
in full as described in clause (i) above or (B) receiving a replacement Option
as set forth in clause (ii)(I). A dissolution or liquidation of the Corporation,
other than a dissolution or liquidation immediately following a sale of all or
substantially all of the assets of the Corporation, which shall be governed by
the immediately preceding sentence, shall cause each Award to terminate. In the
event a Participant receives any unrestricted Shares in satisfaction of
Restricted Shares, any payment in satisfaction of Performance Units, or
exercises any unexpired Option or Options prior to the effectiveness of a sale
of all or substantially all of the Corporation's assets or a merger or
consolidation of the Corporation with another corporation in accordance with
clause (i) of this Section 11, such receipt of unrestricted Shares, such
payment, or exercise of any Option or Options shall be subject to the
consummation of such sale, merger or consolidation. If such sale, merger or
consolidation is not consummated, any otherwise unearned Restricted Shares shall
be deemed not to have been distributed to the Participant, any payment made to
satisfy Performance Units shall be returned to the Corporation, and any
otherwise unexpired Option or Options shall be deemed to have not been
exercised, and the Participant and the Corporation shall take all steps
necessary to achieve this effect including, without limitation, the Participant
delivering to the Corporation the stock certificate representing the Shares
issued with respect to Restricted Shares, the return to the Corporation of any
payments made to the Participant, or upon the exercise of the Option, endorsed
in favor of the Corporation, and the Corporation returning to the Participant
the consideration representing the Purchase Price paid by the Participant upon
the exercise of the Option.
To the extent that the foregoing adjustments relate to securities
of the Corporation, such adjustments shall be made by the Administrator, whose
determination shall be conclusive and binding on all persons.
Except as expressly provided in this Section 11, the Participant
shall have no rights by reason of any subdivision or consolidation of shares of
stock of any class, the payment of any stock dividend or any other increase or
decrease in the number of shares of stock of any class or by reason of any
dissolution, liquidation, merger or consolidation or spin-off of assets or stock
of another corporation, and any issue by the Corporation of shares of stock of
any class, or securities convertible into shares of stock of any class, shall
not affect, and no adjustment by reason thereof shall be made with respect to,
the number or Exercise Price of Shares subject to an Option or the number or
type of Shares subject to an Award of Restricted Shares.
The grant of an Award pursuant to the Plan shall not affect in
any way the right or power of the Corporation to make adjustments,
reclassifications, reorganizations or changes of its capital or business
structure, to merge or consolidate or to dissolve, liquidate, sell or transfer
all or any part of its business or assets.
(b) Acceleration under Certain Circumstances Following a
Change of Control.
Notwithstanding any other provision of the Plan to the contrary
and except as otherwise expressly provided in the applicable Award Agreement,
the restrictions relating to any Restricted Shares, the vesting of any
Performance Units, the vesting or similar installment provisions relating to the
exercisability of any Option, and the restrictions, vesting or installment
provisions relating to any replacement award tendered to a Participant pursuant
to or as a result of, or relating to, a transaction described in the second
paragraph of Section 11(a) hereof shall be waived or accelerated, as the case
may be, and the Participant shall receive unrestricted Shares with respect to
any Restricted Shares, a payment with respect to the value of any Performance
Units, or a similar replacement award, and shall have the right, for a period of
at least thirty days, to exercise such an Option or replacement option in the
event the Participant's employment with or services for the Corporation should
terminate within two years following a Change of Control, unless such employment
or services are terminated by the Corporation for Cause or by the Participant
voluntarily without Good Reason, or such employment or services are terminated
due to the death or Disability of the Participant. Notwithstanding the
foregoing, no Incentive Stock Option shall become exercisable pursuant to the
foregoing without the Participant's consent, if the result would be to cause
such option not to be treated as an Incentive Stock Option.
12. RIGHTS AS A stockholder; NONTRANSFERABILITY.
(a) A Participant or a transferee of an Award shall have no rights as a
stockholder with respect to any Shares covered by such Award until the date of
the issuance of a stock certificate to such Participant or transferee for such
Shares. No adjustments shall be made for dividends (ordinary or extraordinary,
whether in cash, securities or other property) or distributions or other rights
for which the record date is prior to the date such stock certificate is issued,
except as provided in Section 8(c) or Section 11 hereof.
(b) Awards are nontransferable except as provided in this paragraph and
as the Administrator may otherwise provide. Awards may be transferred by will or
by the laws of descent and distribution. Unless otherwise provided in an Award
Agreement, a Participant may give an Award that is not an Incentive Stock Option
to an immediate family member, to a partnership or trust solely benefiting the
Participant or immediate family members, or to an inter vivos trust or
testamentary trust from which the Award (or the Award proceeds) will be
transferred after the Participant's death. An immediate family member is a
Participant's natural or adopted child, stepchild, grandchild, parent,
stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law,
son-in-law, daughter-in-law, brother-in-law, or sister-in-law. A transfer shall
not relieve a Participant from his or her obligations under this Plan or the
applicable Award Agreement with respect to the transferred Award or Award
proceeds.
13. AGREEMENT BY PARTICIPANT REGARDING WITHHOLDING TAXES
(a) No later than the date of exercise of any Option, the distribution
of Shares to a Participant pursuant to a Restricted Share Award, or the payment
of any Performance Units, the Participant shall pay to the Corporation or make
arrangements satisfactory to the Administrator regarding payment of any federal,
state or local taxes of any kind required by law to be withheld, and may satisfy
minimum withholding consequences through the surrender of shares subject to the
Award; provided that an Award Agreement may provide, or the Administrator may in
its discretion permit, a Participant to surrender Shares (including any Shares
subject that the Participant has the present right to receive pursuant to the
Award) having a Fair Market Value equal to the minimum statutory tax withholding
associated with the Award giving rise to the taxable income.
(b) The Corporation shall, to the extent permitted or required by law,
have the right to deduct from any payment of any kind otherwise due to the
Participant any federal, state or local taxes of any kind required by law to be
withheld with respect to an Award.
14. SECURITIES LAW REQUIREMENTS.
(a) Legality of Issuance.
No Shares shall be issued pursuant to any Award unless and until
the Corporation has determined that:
1. it and the Participant have taken all actions
required to register the offer and sale of the
Shares under the Act, or to perfect an exemption
from the registration requirements thereof;
2. any applicable listing requirement of any stock
exchange on which the Common Stock is listed has
been satisfied; and
3. any other applicable provision of state or Federal
law has been satisfied.
(b) Restrictions on Transfer; Representations of Participant;
Legends.
Regardless of whether the offering and sale of Shares under the
Plan has been registered under the Act or has been registered or qualified under
the securities laws of any state, the Corporation may impose restrictions upon
the sale, pledge or other transfer of such Shares (including the placement of
appropriate legends on stock certificates) if, in the judgment of the
Corporation and its counsel, such restrictions are necessary or desirable in
order to achieve compliance with the provisions of the Act, the securities laws
of any state or any other law. In the event that the sale of Shares under the
Plan is not registered under the Act but an exemption is available which
requires an investment representation or other representation, each Participant
shall be required to represent that any Shares being acquired by the Participant
are being acquired for investment, and not with a view to the sale or
distribution thereof, and to make such other representations as are deemed
necessary or appropriate by the Corporation and its counsel. Stock certificates
evidencing Shares acquired under the Plan pursuant to an unregistered
transaction shall bear the following restrictive legend (or similar legend in
the discretion of the Administrator) and such other restrictive legends as are
required or deemed advisable under the provisions of any applicable law:
"THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933. THESE SECURITIES HAVE BEEN ACQUIRED
FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION AND MAY NOT BE
OFFERED FOR SALE, SOLD, PLEDGED OR OTHERWISE TRANSFERRED IN THE ABSENCE
OF AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER THE
SECURITIES ACT OF 1933 OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY
IN FORM AND CONTENT TO THE ISSUER THAT SUCH REGISTRATION IS NOT REQUIRED
UNDER SUCH ACT."
Any determination by the Corporation and its counsel in
connection with any of the matters set forth in this Section 13 shall be
conclusive and binding on all persons.
(c) Registration or Qualification of Securities.
The Corporation may, but shall not be obligated to, register or
qualify the sale of Shares under the Act or any other applicable law. The
Corporation shall not be obligated to take any affirmative action in order to
cause the sale of Shares under the Plan to comply with any law.
(d) Exchange of Certificates.
If, in the opinion of the Corporation and its counsel, any legend
placed on a stock certificate representing Shares sold under the Plan is no
longer required, the holder of such certificate shall be entitled to exchange
such certificate for a certificate representing the same number of Shares but
without such legend.
15. AMENDMENT OF THE PLAN; MODIFICATION OF AWARDS.
The Board may from time to time, with respect to any Shares at
the time not subject to Awards, suspend or discontinue the Plan or revise or
amend it in any respect whatsoever.
Within the limitations of the Plan, the Administrator may modify any Award,
accelerate the vesting of any Restricted Share Award or the rate at which an
Option may be exercised, or extend or renew outstanding Options. The foregoing
notwithstanding, no modification of an Award shall, without the consent of the
Participant, adversely alter or impair any rights or obligations under any Award
previously granted to the Participant.
16. APPLICATION OF FUNDS.
The proceeds received by the Corporation from the sale of Common
Stock pursuant to the exercise of an Option will be used for general corporate
purposes.
17. APPROVAL OF STOCKHOLDERS.
The adoption of this restated Plan is subject to approval by the
stockholders of the Corporation.
18. EXECUTION.
To record the adoption of the amended and restated Plan by the
Board on November 17, 2003 the Corporation has caused its authorized officers to
affix the corporate name and seal hereto.
BIOENVISION, INC.
By: __________________________________
Name:
Title:
By: __________________________________
Name:
Title:
ANNEX C
BIOENVISION, INC.
Audit Committee Charter
I. Organization
This charter governs the operations of the Audit Committee of the Board
of Directors of Bioenvision Inc. (the "Company"). The Committee shall review and
reassess this Charter at least annually and obtain the approval of the Board of
Directors of the Company (the "Board"). The Committee shall comprise at least
three Directors appointed by the Board of Directors. Each member of the
Committee shall be independent of management and the Company, in accordance with
the Nasdaq Marketplace Rules. Generally, members of the Committee shall be
considered independent if they have no relationship that may interfere with the
exercise of their independence from management and the Company. All Committee
members must be able to read and understand fundamental financial statements,
including the Company's consolidated balance sheet, statement of earnings,
statements of stockholders' equity and comprehensive income and statements of
cash flows. At least one member shall have past employment experience in finance
or accounting, requisite professional certification in accounting, or other
comparable experience or background, including a current or past position as a
chief executive or financial officer or other senior officer with financial
oversight responsibilities.
II. Statement of Policy
The Audit Committee shall provide assistance to the Board of Directors
in fulfilling their oversight responsibility to the stockholders, potential
stockholders and the investment community relating to corporate accounting,
reporting practices of the Company and the quality and integrity of the
financial reports of the Company. In so doing, the Committee is responsible for
maintaining free and open communication between the Committee, independent
auditors, the internal auditors and management of the Company. In discharging
its oversight role, the Committee is empowered to investigate any matter brought
to its attention with full access to all books, records, facilities, and
personnel of the Company and the power to retain outside counsel or other
experts for this purpose.
III. Meetings
The Committee shall meet at least [4] times a year and as many
additional times as the Committee deems necessary. The Committee will meet in
separate executive sessions with the chief financial officer, independent
auditors and internal auditors at least once each year and at other times when
considered appropriate. The Committee shall maintain minutes or other records of
its meetings and other activities.
IV. Responsibilities and Processes
A. General
The primary responsibility of the Audit Committee is to oversee the
Company's financial reporting process on behalf of the Board and report the
results of their activities to the Board. Management is responsible for
preparing the Company's financial statements and the independent auditors are
responsible for auditing those financial statements. The Committee in carrying
out its responsibilities believes its policies and procedures should remain
flexible, in order to best react to changing conditions and circumstances. The
Committee should take the appropriate actions to set the overall corporate
"tone" for quality financial reporting, sound business, risk practices, and
ethical behavior. Additionally, the Committee shall investigate any
matter brought to its attention within the scope of its duties, with the power
to retain outside counsel for this purpose if, in its judgment, that is
appropriate.
B. Independence of Auditors
The Committee shall have a clear understanding with management and the
independent auditors that the independent auditors are ultimately accountable to
the Board and the Audit Committee, as representatives of the Company's
stockholders, The Committee shall have the ultimate authority and responsibility
to evaluate and, where appropriate, replace the independent auditors. The
Committee shall discuss with the auditors their independence from management and
the Company and receive from the auditors, at least annually, a formal written
statement delineating all relationships between the auditors and the Company
consistent with the Independence Standards Board Standard 1. Annually, the
Committee shall review and recommend to the Board the selection of the Company's
independent auditors.
C. Financial Reporting Process
The Committee shall meet with the independent auditors and the Company's
management responsible for the financial statements to review the scope of the
proposed audit and timely quarterly reviews for the current year and the
procedures to be utilized, the adequacy of the independent auditor's
compensation, and at the conclusion thereof, review such audit or review,
including any comments or recommendations of the independent auditors. The
Committee shall provide sufficient opportunity for the independent auditors and
the internal auditor, if any, to meet with the members of the Audit Committee
without members of management present. Among the items to be discussed in these
meetings are the independent auditors' evaluation of the Company's financial,
accounting, and internal auditing personnel, if any, and the cooperation that
the independent auditors received during the course of audit.
Also, the Committee shall discuss with management, the internal
auditors, and the independent auditors the adequacy and effectiveness of the
accounting and financial controls, and elicit any recommendations for the
improvement of such internal controls or particular areas where new or more
detailed controls or procedures are desirable. The Committee shall inquire of
management and the independent auditors about significant risks or exposures
faced by the Company and assess the steps management has taken to minimize such
risks or exposures. Further, the Committee shall meet separately with the
internal auditors and the independent auditors, with and without management
present, to discuss the results of their examinations.
The Committee shall report the results of the annual audit to the Board
of Directors. If requested by the Board, invite the independent auditors to
attend the full Board of Directors meeting to assist in reporting the results of
the annual audit or to answer other Directors' questions (alternatively, the
other Directors, particularly the other independent Directors, may be invited to
attend the Audit Committee meeting during which the results of the annual audit
are reviewed).
The Audit Committee's responsibilities also include reviewing reports
received from regulators and other legal regulatory matters that may have a
material effect on the financial statements or related company compliance
policies.
D. Reports Review
1. The Committee shall review the quarterly financial statements
with the Company's management responsible for the financial
statements and the independent auditors prior to the filing of
the Form 10-Q(SB) (or prior to the press release of results,
if possible) to ensure that the independent auditors do not
take exception to the disclosure and content of the financial
statements, and discuss any other matters required to be
communicated to the Committee by the auditors. The chair of
the Committee may represent the entire Committee for purposes
of this review.
2. The Committee shall review the financial statements to be
contained in the annual report of Form 10-K(SB) to
stockholders with management and the independent auditors to
determine that the independent auditors are satisfied with the
disclosure and content of the financial statements to be
presented to the stockholders. Review with the Company's
management responsible for the financial statements and the
independent auditors the results of their timely analysis of
significant financial reporting issues and practices,
including changes in, or adoptions of, accounting principles
and disclosure practices, and discuss any other matters
required to be communicated to the Committee by the auditors.
Also review with the Company's management responsible for the
financial statements and the independent auditors their
judgments about the quality, not just acceptability, of
accounting principles and the clarity of the financial
disclosure practices used or proposed to be used, and
particularly, the degree of aggressiveness or conservatism of
the Company's accounting principles and underlying estimates,
and other significant decisions made in preparing the
financial statements.
3. If deemed appropriate after review and discussion, the
Committee will recommend to the Board that the financial
statements be included in the Company's Annual Report on Form
10-K(SB).
E. Proxy Statement Report
After preparation by management, the Committee shall approve the
Committee report required by the rules of the Securities and Exchange Commission
to be included in the Company's annual proxy statement. The Committee report
shall disclose whether (1) the Committee had reviewed and discussed with
management and the independent auditors, as well as discussed within the
Committee (without management or the independent auditors present), the
financial statements and the quality of accounting principles and significant
judgments affecting the financial statements; (2) the Committee discussed with
the auditors the independence of the auditors; and (3) based upon the
Committee's review and discussions with management and the independent auditors,
the Committee had recommended to the Board of Directors that the audited
financials be included in the Company's annual report on Form 10-K(SB). This
charter will be included as an appendix to the proxy statement at least once
every three years.